Subject Index

Page references followed by t indicate a table.

ABC (Attribution Bias Context) model, 275
Abstinence violation effect (AVE), treatment in case of, 138–140
Acetylcholinesterase inhibitors, 854–855
Activity levels
Bipolar Disorders and changes in, 478–479
exercise programs to increase, 395–396
Addition Severity Index (ASI), 776
ADDRESSING (acronym for within-group) diversity factors, 15
ADHD (Attention-Deficit/ Hyperactivity Disorder)
additional characteristics of, 263–268
Autism Spectrum Disorder (ASD) and, 219–220, 222, 226
Bipolar Disorders differential diagnosis with, 513, 514t, 515–516
clinical presentation, 254–258
description and demographics of, 251–252
diagnostic considerations, 284–289
epidemiology of, 253–254
etiology of, 268–272
historical overview of, 252–253
intake considerations, 273t, 284
onset, course, and life span considerations of, 261–263
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) differential diagnosis and, 705–706
specifiers of, 258–260
treatment, 289–309
See also Children
ADHD (Attention-Deficit/ Hyperactivity Disorder) comorbid disorders
anxiety and mood disorders, 282–283
Autism Spectrum Disorder (ASD) and, 284
Bipolar Disorders, 510–511
disruptive disorders, 281–282
Eating Disorders, 664
learning disorders, 282
Oppositional Defiant Disorder (ODD) and Conduct Disorders (CD), 703
See also Comorbidity
ADHD characteristics
cognitive challenges, 261
school, academic, and occupational difficulties, 264
self-regulation and rule-governed behavior, 263–264
ADHD specifiers combined (ADHD-C), 259
inattentive (ADHD-I), 259–260
predominantly hyperactive/impulsive (ADHD-H/I), 260
subtypes and three severity, 258–259
ADHD treatment
of adults with ADHD, 306–308
of comorbid disorders and conditions, 308–309
family interventions, 299–304
issues to consider in, 289
medication, 289–293
medication side effects, 293–295
multimodal treatment and MTA (Multimodal Treatment Study of Children with ADHD), 295–297, 302
psychosocial interventions, 298–299
Adjunctive treatment (Bulimia Nervosa), 675
Adjunctive Disorders
anxiety, OCD, and trauma disorders differential diagnosis of, 706
description of, 605t
Adolescents
ADHD (Attention-Deficit/ Hyperactivity Disorder), 262, 263–268
Anorexia Nervosa (AN), 647–648
Autism Spectrum Disorder (ASD), 196, 243t–245
Binge-Eating Disorder (BED), 653
Bipolar Disorders, 482–484
Bulimia Nervosa (BN), 651
childhood-onset Schizophrenia, 329–332
Conduct Disorder (CD), 689, 690–691
confidentiality issue related to, 12
developmental variations in relevant cognitive processes of, 51t
diagnoses increasing risk of suicide in, 125
diagnosis determination
developmental or life span recommendations on, 88t
informed consent and, 10–11
intake and interviewing considerations related to, 46–52
Major Depressive Disorder (MDD), 407–408
observations to make during interactions between parent and, 48t
Oppositional Defiant Disorder (ODD), 682–683, 690–691
Panic Disorder, 558–559
Persistent Depressive Disorder (Dysthymia), 412
premature termination of treatment for, 161–162
PTSD (Posttraumatic Stress Disorder), 585
substance use disorders, 754–755, 759–761
understanding of treatment and initial interview by, 46
See also Children; College students
Adolescent Supplement to the National Comorbidity Survey–Replication (NCS–R), 402, 537
Adult Antisocial Personality Disorder (ASPD), 692
Adult children of alcoholics (ACOA), 770–771
Adult Children of Alcoholics (12-step group), 800
**Subject Index**

**Adult Development and Aging** (Whitbourne and Whitbourne), 54

Adults

ADHD (Attention-Deficit/ Hyperactivity Disorder) and, 262–263, 306–308
Adult Antisocial Personality Disorder (ASPD), 692
Adult survivors of sexual abuse, 132, 138–140
Autism Spectrum Disorder (ASD) and, 196, 208, 217–218, 244r, 245–249
Conduct Disorder (CD), 691–692
delirium, 815
PTSD (Posttraumatic Stress Disorder), 585
substance use disorders, 754–757
See also Older adults
Adult Spectrum Disorder in Adults
American Academy of Child and Adolescent Psychiatry (AACAP), 211
American Association on Intellectual and Developmental Disabilities (AAIDD), 9. 12, 109
American Association of Marriage and Family Therapists (AAMFT), 9. 12, 109
American Association on Intellectual and Developmental Disabilities (AAIDD), 223
American Counseling Association (ACA), 9. 12, 109
American Psychiatric Association (APA)
on assessing stressors and coping skills, 29
on clinician factors that may impact treatment, 109
on clinician familiarity with confidentiality, 12
on DSM-5 cultural interview, 33
on DSM-5 used during intake interview, 4
on informed consent, 9
on intoxication and withdrawal, 740
Presidental Task Force on Evidence-Based Practice, 153
The Road to Resilience by, 38, 116
on taking a medical history, 31
See also DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition); specific disorder

Americans with Disabilities Act (1990), 298, 304
Anorexia Nervosa (AN)
capacity to consent, 658–659
clinical presentation, 643–646
comorbidity, 661, 663–664
description of, 638, 639
diagnostic considerations, 664–667
epidemiology, 641–642
treatment, 654–657
intake considerations, 657–661
interview and assessment strategies, 659–661
medication, 673
onset, course, and life span considerations, 646–648
subtypes and specifiers, 653–654
weight gain issue during treatment, 671
See also Eating Disorders
Antabuse (disulfiram), 788
Anti-anxiety medication
anxiety, OCD, and trauma disorders, 618
buspirone, 618
Anticipatory interpretations, 162
Anticonvulsants
Bipolar Disorders, 525–526
description and forms of, 525
side effects of, 526
Antidepressant medication
antidepressant black box warning consideration of, 454–455
anxiety, OCD, and trauma disorders, 613–616
Bipolar Disorders, 527
Bulimia Nervosa (BN), 675
depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 415, 444, 447–455
increased suicide risk and, 454–455
MAOIs (monoamine oxidase inhibitors), 415, 423, 448, 452, 613, 616
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 717
SNRIs (serotonin norepinephrine reuptake inhibitors), 451, 612, 613–614, 615–616
SSRIs (selective serotonin reuptake inhibitors), 448, 449–451, 454, 612, 613–614, 615, 675, 947
TCAs (tricyclic antidepressants), 292, 415, 448, 449, 615, 616
treatment resistant depression consideration of using, 452–454
Antipsychotics
Bipolar Disorders, 526–527
delirium, 850–851
description and forms of, 526
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 717
Antisocial Personality Disorder (ASPD), 708, 785
clinical presentation, 87t, 888–889
common comorbidities, 923r
description of, 888
interview considerations for, 916
onset, course, and life span considerations, 889–890
specific treatment interventions for, 935, 939–940
Antisocial Process Screening Device (APSD), 702t
Antisocial traits and behaviors, 872–873
Anxiety disorders
ADHD comorbidity with, 282–283
ADHD differential diagnosis with, 286t, 287–288
Autism Spectrum Disorder (ASD) and, 219, 223t, 225
Bipolar Disorders, 511–512
central clinical and discriminating features, 607–609
diagnostic considerations, 603–609t
Eating Disorders comorbidity, 661, 663
Eating Disorders differential diagnosis of, 665
etiology, 586–593
historical overview of, 538–539
intake considerations, 593–596
interview and assessment strategies, 29, 596–603
introduction to, 537–538
medical conditions that resemble, 81t
Oppositional Defiant Disorder (ODD) and Conduct Disorders (CD) comorbidity with, 704
Personality Disorders
comorbidity, 923t, 924
Schizophrenia and other psychotic disorders and symptoms of, 366–367
substance use disorder
comorbidity with, 783–784
treatment, 610–635
See also Generalized Anxiety Disorder (GAD); Panic Disorder; Social Anxiety Disorder (Social Phobia); Specific Phobia
Anxiety symptoms intake interview, 29
Anxiolytics
demographics and statistics on the use of, 728
intoxication symptoms, 741t, 753–754
medical complications that can arise from, 734t
withdrawal symptoms, 742t, 754
See also Substance use disorders
Aphasia, 817–818
Applied Behavior analysis (ABA), 233
Applied tension, 620–621
Aripiprazole, 526
Art therapy, 860
Asian Americans
ALDH2*2 allele in, 764
substance use disorders, 759
See also Racial/ethnic differences
Asperger’s Disorder, 191
Assaulted Staff Action Program (ASAP), violence triad data from the, 7
Assertive Community Treatment (ACT) model, 379–380, 393, 397
Assessment
abuse and neglect, 135–138
Chronological Assessment of Suicidal Events (CASE), 121
crisis intervention, 116t
danger to self and others, 118t–119, 120t
functional impairment, 152
of high-risk behaviors related to ADHD, 274
prior violent behavior, 123t
psychological, 146–147
substance use disorders, 774–785
suicide attempt and ideation, 123t–124, 128–129
treatment effectiveness and outcome, 106t, 158–165
See also Interview and assessment strategies
Assessment measures
ADHD (Attention-Deficit/Hyperactivity Disorder), 277–281, 278t–280t
for anxiety, OCD, and trauma disorders, 598t–599t
Assessment Measures section (DSM-5), 73
for Autism Spectrum Disorder (ASD), 213, 213–218
behavioral avoidance tests, 597
for Bipolar Disorders, 506t–507t
CAGE questions, 30, 777t
Chronological Assessment of Suicidal Events (CASE), 121
CLIENTS mnemonic on presenting problem(s), 26–27t, 48, 146
communication disorders, 224–225
Diagnostic Interview Schedule for DSM-IV (DIS-IV), 56t
Diagnostic Interview Schedule for Children and DSM-IV (DISC-IV), 57t
for Eating Disorders, 661, 662t–663t
Family Inventory of Life Events (FILE), 28
FIDO (Frequency, Intensity, Duration, and Onset), 28, 90–91, 146
5-point Clinician-Rated Dimensions of Psychosis
Symptom Severity scale in the DSM-5, 337, 341
Folstein Mini-Mental Status Exam (MMSE), 43, 456, 820
for intellectual disability, 223–224
International personality Disorder Examination (IPDE), 56t
Inventory of Potential Communicative Acts (IPCA) questionnaire, 207
Kiddie Schedule for Affective Disorders and Schizophrenia (K–SADS), 55, 57t
mental status examination (MSE), 4, 39–44, 53, 207
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 701–703
Personality Disorders, 919–922
to predict violent behavior, 129
SAD PERSONS Scale, 121
Schedule for Affective Disorders and Schizophrenia (SADS), 56t
for Schizophrenia and other psychotic disorders, 359t–360t
Social Readjustment Rating Scale, 28
Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD), 56t
Structured Clinical Interview for the DSM-5 (SCID-5), 55, 56t
substance use disorders, 777t–778t
for suicide assessment, 121, 128–129
Atomoxetine (Strattera), 292
Attending (intake interview), 19–20
Attention/concentration
ADHD deficits in, 256, 275–276
ASD and joint attention deficits, 183–184, 205
delirium, 811
Mental status examination (MSE) on, 42t
Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (Barkley), 276
Attribution Bias Context (ABC) model, 275
Auditory hallucinations, 319
Autism and Developmental Disabilities Monitoring Network (ADDMN) [CDC], 173
Autism Diagnostic Interview–Revised (ADI-R), 215–216
Autism Diagnostic Observation Schedule–2 (ADOS-2), 214t, 216
Autism Society of America, 177, 228
Autism Speaks, 177, 208, 209, 228, 241–242, 243
Autism Spectrum Disorder (ASD) additional features of, 197–198
ADHD comorbidity with, 284
clinical presentation of, 179–190

Autism Spectrum Disorder (ASD) (continued)
description and demographics of, 173–174
diagnostic considerations, 220–226
epidemiology of, 177–179
etiology of, 199–206
historical overview of the, 174–177
intake considerations, 206–210
interview and assessment strategies, 210–220
restrictive and repetitive behaviors (RRBs) and, 186–187, 189, 206
role of grandparents as caregivers and supports, 242–243
specifiers of, 190–197
treatment principles and interventions, 226–249
See also Children
Autism Spectrum Disorder (ASD) interview/assessment in adults, 217–218
assessment measures, 213
developmental assessment, 211–213
issues to consider for, 210–211
Level 1 screening, 213–215
Level 2 screening, 215–217
screen for comorbid disorders, 218–220
Autism Spectrum Quotient (AQ), 217
“Autistic Disturbances of Affective Contact” study (Kanner), 175
Avoidance (including agoraphobia)
Anxiety Disorders, 556–557
behavioral avoidance tests, 597
Avoidant, 874–875
Avoidant Personality Disorder
clinical presentation, 878r, 899–900
common comorbidities, 923r
description of, 898–899
interview considerations for, 918–919
onset, course, and life span considerations, 906
specific treatment interventions for, 935r, 949–950
Barratt Aggressive Acts Questionnaire (AAQ), 702r
BASIC I.D., 156
BASIC program (ODD and CD), 710, 711
Bath salts (illicit drugs), 723
Beck Anxiety or Depression Scales, 280–281
Beck Depression Inventory, Second Edition (BDI-II), 145
Beck Hopelessness Scale, 128
Beck Scale for Suicide Ideation, 128
Beck’s cognitive theory of depression, 425, 499
Behavioral avoidance tests, 597
Behavioral family or couples therapy (BCT), 796–798
Behavioral inhibition deficit, 271
Behavioral observations of substance use, 779
Behavioral parent training (BPT), 299–304
Behavioral Skill Training and Rehearsal, 404
Behavioral weight loss therapy, 677
Benzodiazepines anxiety, OCD, and trauma disorders, 616–618
delirium, 851
medical detoxification using, 788
neuropsychological impairment due to, 739
Bereavement and depression, 441r, 443–444
Best Practices in Mental Health (2010 special issue), 114
Binge-Eating Disorder (BED)
capacity to consent, 658–659
clinical presentation, 651–652
comorbidity, 661, 663–664
description of, 638, 639
diagnostic considerations, 664–667
epidemiology, 641, 643
etiology, 654–657
intake considerations, 657–661
interview and assessment strategies, 659–661
medication, 677
onset, course, and life span considerations, 652–653
psychotherapy, 676–677
subtypes and specifiers, 654
See also Eating Disorders
Biological bases
ADHD (Attention-Deficit/Hyperactivity Disorder), 268–271
anxiety, OCD, and trauma related disorders, 586–590
Autism Spectrum Disorder (ASD), 199–203
Bipolar Disorders, 495–499
depressive disorders, 422–425
Eating Disorders, 654–656
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) differential diagnosis and, 705r
treatment, 520–535
Bipolar Disorders I and II
central clinical and discriminating features of, 518–519, 520
clinical presentation, 475–479
depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 441r, 442–443
diagnostic considerations, 513–520
differentiation between, 475–492, 481
epidemiology, 474
etiology: biological bases, 395, 495–499
etiology: psychological theories, 499–501
specifiers, 484–492
treatment, 520–535
See also Cyclothymic Disorder
Bipolar Disorder specifiers
anxious distress, 486–487
atypical features, 486
listed, 485r
Mood Disorders, 518–519
mixed features, 487–488
peripartum onset, 489–490
psychotic features, 488–489
rapid cycling, 491–492
severity/remission, 484–485
Bipolar Disorder treatment
electroconvulsive therapy (ECT), 527–528
general principles in, 520–521
medication, 521–527
psychotherapy, 528–535
Black box warning, antidepressants, 454–455
Blessed Dementia Scale, 820
Blood alcohol concentration (BAC), 741, 742, 742–743, 744
Blueprint for Action to Prevent Youth Violence, 718
Blunted or flattened affect, 317r, 322
BMI (body mass index), 396
Body Dysmorphic Disorder (BDD), 371, 373
Body language. See Nonverbal communication
Borderline, 873
Borderline Personality Disorder
Bipolar Disorders differential diagnosis, 515r, 518
clinical presentation, 878r, 891–892
common comorbidities, 923r
description of, 890–891
Dialectical Behavior Therapy (DBT) for, 935r, 942–944
interview considerations for, 916–917
medication for, 947–948
metallization-based treatment for, 935r, 945–946
onset, course, and life span considerations, 892–894
schema-focused therapy (SFT), 935r, 946–947
specific treatment interventions for, 935r, 940–948
substance use disorders comorbidity with, 785
Transference-Focused Psychotherapy (TFP), 935r, 944–945
Boys/men. See Gender differences
Brain structure/functioning
ADHD (Attention-Deficit/Hyperactivity Disorder) and abnormalities of the, 269–270
anxiety, OCD, and trauma related disorders, 586–588
Autism Spectrum Disorder (ASD), 200–202
Bipolar Disorders, 498
depressive disorders and abnormalities, 425
Eating Disorders, 655–656
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 693–694
Brief Psychiatric Rating Scale (BPRS), 359r
Brief Psychotic Disorder
Catatonia Associated with Brief Psychotic Disorder, 341
clinical presentation of, 339
onset, course, and life span considerations, 339–341
Schizoaffective Disorder and, 315–316
“With Catatonia” specifier and other specifiers, 341
Brief Symptom Inventory, 145
Brown Attention-Deficit Disorder Scale., 277
Bulimia Nervosa (BN)
capacity to consent, 658–659
clinical presentation, 648–650
comorbidity, 661, 663–664
description of, 638, 639
diagnostic considerations, 664–667r
epidemiology, 641, 643
etiology, 654–657
intake considerations, 657–661
medication, 675
onset, course, and life span considerations, 650–651
subtypes and specifiers, 654
weight stabilization issue during treatment of, 673–674
See also Eating Disorders
Bulimia Test Revised (BULIT-R), 662
Bullying, 268
Buprenorphine, 791
Burns Anxiety Inventory, 145
Buspirone, 618
CAGE questions, 30, 777r
California Department of Disabilities CDERs (Client Development and Evaluation Reports) on ASD by, 177–178
practice guidelines on ASD assessment, 211
Cannabis
demographics and statistics on use of, 726
intoxication symptoms, 741t, 744–745
medical complications that can arise from, 734t
neuropsychological impairment due to, 737–738
THC in, 744, 763
withdrawal symptoms, 742t, 745
See also Substance use disorders
Capgras syndrome, 820
Carbamazepine, 525
Caregivers. See Family caregivers
Case conceptualization
case formulation report and, 147r–148
identifying and prioritizing problems, 143–146, 147r
orientation and, 148–149
overview of, 106r, 142–143
role of psychological assessment, 146–147
Case formulation report, 150r
Catatonia
Catatonia Associated with Brief Psychotic Disorder, 341
catatonic behavior, 321
Major Depressive Disorder (MDD) with, 420–421
Catatonia Associated with Brief Psychotic Disorder, 341
Caucasians
Project REACH on Alzheimer’s caregivers, 861, 862
substance use disorders, 757, 761
See also Racial/ethnic differences
Cautionary tales, 163
Center-based ASD programs, 236–237
Center for Outreach and Services for the Autism Community (COSAC), 228
Centers for Disease Control and Prevention (CDC)
on alcohol-related causes of death gender differences, 743
on ASD and vaccine controversy, 203
Autism and Developmental Disabilities Monitoring Network (ADDMN) of the, 173
National Centers of Excellence in Youth Violence Prevention funded by, 717
state-by-state prevalence rates for ASD, 178
Striving To Reduce Youth Violence Everywhere (STRYVE) Strategies Selector Tool, 718
on suicide rates, 117, 120
Changed set point model, 764
Checklist for Autism in Toddlers (CHAT), 213, 214r
Child complaint and presenting problem(s), 24r, 26
Child abuse and neglect
child protective services in case of, 132
clinician responsibilities, 135–140
as condition that may be a focus of clinical attention, 95t
definitions of, 133r
mandated reporting in case of, 138, 139t
substance abuse disorders and, 781–782
See also Abuse and neglect;
Trauma and stressor related disorders
Child and Adolescent Psychiatric Assessment (CAPA), 277
Childhood Autism Rating Scale (CARS/CARS2), 214r, 216
Childhood development
developmental milestones of, 48–49
as diagnosis determination factor, 80t, 84–89
interviewing parents about their child’s, 48
variations in relevant cognitive processes during, 51r
Child protective services, 132
Children
Anorexia Nervosa (AN), 647–648
Binge-Eating Disorder (BED), 653
Bipolar Disorders, 482–483
Bulimia Nervosa (BN), 651
CBASP similarities between clinically depressed and preoperational, 463t
childhood-onset Schizophrenia, 329–332
Conduct Disorder (CD), 688–690
confidentiality issue related to, 12
delirium, 815

Children (continued)
diagnosis determination
developmental or life span recommendations on, 88
Generalized Anxiety Disorder (GAD), 564
Hoarding Disorder, 575–576
informed consent and, 10–11
intake and interviewing considerations related to, 46–52
Major Depressive Disorder (MDD), 407–408
observations to make during interactions between parent and, 48
Obsessive-Compulsive Disorder (OCD), 570–571
Oppositional Defiant Disorder (ODD), 682–683, 688–690
Panic Disorder, 558–559
Parent-Child Relational Problems, 286r, 288–289
Persistent Depressive Disorder (Dysthymia), 412
premature termination of treatment for, 161–162
PTSD (Posttraumatic Stress Disorder), 585
Social Anxiety Disorder (Social Phobia), 552r–553
Specific Phobia, 545–546
substance use disorders, 759–761
understanding of treatment and substance use disorders, 759–761
Specific Phobia, 545–546
substance use disorders, 610–612
understanding of treatment and substance use disorders, 610–612
Specific Phobia, 543–544
substance-related disorders, 728–732
substance use disorders, 728–739
Clinician Administered PTSD Scale for DSM-5 (CAPS-5), 599
release of initial interview information, 13
Client resistance
two guiding principles to enhance communication in case of, 18
motivational interviewing to deal with, 17
"rolling with," 17
See also Rapport
Clients
risks interventions for, 106r, 114–142
determine what you know and don’t know about your, 3–4
factors that may impact treatment, 110–113
identifying information on, 24r, 26
initial interview of, 3–58
SNAPS consideration for treatment plan of, 156
termination initiated by, 167–168
See also Therapeutic relationship
CLIENTS mnemonic on presenting problem(s), 26–27r, 48, 146
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, 365, 384, 395
Clinical Interviewing (Sommers-Flanagan), 109
Clinical presentation
ADHD (Attention-Deficit/Hyperactivity Disorder); Adolescents; Autism Spectrum Disorder (ASD); Parents; Play
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), 298
Child sexual abuse
description of, 132
mandated reporting laws, 138, 139t
Chlorpromazine (Thorazine), 380
Chronic Major Depressive Disorder (MDD-C), 402, 410–411, 412
Chronological Assessment of Suicidal Events (CASE), 121
Classical (Pavlovian) conditioning to understand, 766
Classification. See Psychiatric classification
Client history
answering client questions during intake interview and, 22–23
as condition that may be a focus of clinical attention, 95r–96t
intake interview questions on, 24t, 25–39
See also Interview and assessment strategies
Client records
HIPAA Privacy Rule on, 11
initial interview safety and what to look for in a review of, 7t
Clinician-Rated Dimensions of Psychosis Symptom
Clinician-Rated Dimensions of Psychosis Symptom Severity, 359
Clinician responsibilities
abuse and neglect, 135–140
Suicide interventions and, 118
Social Anxiety Disorder (Social Phobia), 547–548
Clinicians
considerations when working with schools, 305
Cultural competence of, 14–16
factors that may impact treatment, 109, 112
intake and interviewing skills of, 3–58
as similar to being a detective trying to solve a mystery, 3
therapist-initiated termination, 167
See also Therapeutic relationship
Clinician’s Thesaurus (Zuckerman), 156
Cloninger’s typology of alcoholism, 75–76
Closed-ended questions, 21
Club drugs, 722–723
Clubhouse model, 397
Coca-Cola, 745
Cocaine and other stimulants
demographics and statistics on, 725–726
intoxication symptoms, 741r, 745–747
medical complications that can arise from, 734
neuropsychological impairment due to, 737
withdrawal symptoms, 742r, 747
See also Substance use disorders
Cocaine Anonymous, 800
Cognitive and behavioral theories
depressive disorders, 425–427
Eating Disorders, 643–646
Eating Disorders, 648–650, 651–652
Generalized Anxiety Disorder (GAD), 560–563
Hoarding Disorder, 571–574
Major Depressive Disorder (MDD-C), 403–405
Major Neurocognitive Disorders (Major NCD), 817–821
Obsessive-Compulsive Disorder (OCD), 565–568
Oppositional Defiant Disorder (ODD), 681–682
Persistent Depressive Disorder (Dysthymia), 409–411
PTSD (Posttraumatic Stress Disorder), 577–582
Schizoaffective Disorder, 334–335
Schizophrenia, 316–323
Schizophreniform Disorder, 337–338
Specific Phobia, 543–544
substance-related disorders, 728–732
substance use disorders, 728–739
Clinician Administered PTSD Scale for DSM-5 (CAPS-5), 599
...
...academic difficulties; intake and interviewing; (Sue and Psychotherapy Disruptive and conduct disorders, 387–389; substance use disorder, 792–793, 795; TORDIA study on SSRIs used with, 454; See also Psychotherapy Cognitive disorders depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 439, 440r, 441 schizophrenia and other psychotic disorders and, 370, 371r, 372; Schizophrenia and other psychotic disorders differential diagnosis of, 370, 371r, 372; Cognitive features developmental variations in relevant childhood, 51r; Generalized Anxiety Disorder (GAD), 561–562; Hoarding Disorder, 573–574; Obsessive-Compulsive Disorder (OCD), 567–568; Cognitive rehabilitation Major NCD-AD, 858; overview of programs for Major NCD-AD, 858–860; Cognitive remediation description and origins of, 394 for Schizophrenia and other psychotic disorders, 394–395; Cognitive restructuring Obsessive-Compulsive Disorder (OCD), 630; Social Anxiety Disorder (Social Phobia), 623–624; Cognitive symptoms Bipolar Disorders, 477–478; delirium, 811–812; Generalized Anxiety Disorder (GAD), 561; intake interview on, 29; Major Depressive Disorder (MDD-C), 404–405; psychotic disorders and, 347–348; PTSD (Posttraumatic Stress Disorder), 581; Social Anxiety Disorder (Social Phobia), 548–549; Cognitive theories anxiety, OCD, and trauma related disorders, 591–592; Beck’s cognitive theory of depression, 425, 499; Bipolar Disorders, 499–501; substance use disorders, 767–769; Cognitive triad, 425; Collaborative Psychiatric Epidemiological Studies, 92 College students ADHD challenges for, 265–266; adult children of alcoholics (ACOA), 771; Autism Spectrum Disorder (ASD) challenges in, 245–246; See also Academic difficulties; Adolescents; Combating Autism Reauthorization; Act or Public Law 112–32, 177; COMBINE study, 789; Comic Strip Conversations (C. Gray), 240; Common liability model of substance use, 756; Communication five guiding principles to enhance client, 18; listening and attending to enhance, 19–20; suicide risk and inability to see alternatives and, 126–127; See also Intake and interviewing; Language; Communication deficits Autism Spectrum Disorder (ASD), 181; Autism Spectrum Disorder (ASD) with and without, 181–192; instruments for assessing disorders and, 224–225; language disturbances, 811–812; Community outpatient setting, 92r; Comorbidity anxiety, OCD, and trauma disorders, 600–603; Autism Spectrum Disorder (ASD), 218–220; Bipolar Disorders, 410–513; DSM-5 definition of, 73; Eating Disorders, 661, 663–664; multiple and comorbid disorders, 100–102; Personality Disorders, 922–925; principal diagnosis and, 102; screen for Schizophrenia and other psychotic disorders, 364–368; substance use disorders, 782–785; See also ADHD (Attention-Deficit/Hyperactivity Disorder) comorbid disorders; Compassionate Allowance (CAL), 397; Competence cultural, 14–16; intake interview on resilience, strengths, challenges, and, 24r, 37–39; Concentration. See Attention/concentration; Conditions for Future Study section (DSM-5), 73, 74; Conduct Disorder (CD) central clinical and discriminating features, 707r; classified as Adult Antisocial Personality Disorder (ASPD), 692; clinical presentation, 683–684; comorbid disorders, 703–704; diagnostic considerations, 704–708; environmental factors, 698; epidemiology, 681; etiology, 692–698; family factors, 695–696; impairment, 684; intake considerations, 698–701; interview and assessment strategies, 701–703; medication, 716–717; onset, course, and life span considerations, 688–692; peer relationships, 696–697; poor peer relationships, 687–688; risk and protective factors for, 697t; specifiers, 685–687; treatment, 708–717; See also Disruptive and conduct disorders; Confidentiality ADHD (Attention-Deficit/ Hyperactivity Disorder), 274; child clients and, 12; conditions in which it may be breached, 12; HIPAA Privacy Rule on, 11; intake interviews and, 11–13; Oppositional Defiant Disorder (OCD) and Conduct Disorder (CD), 699–701; treatment plan, 156, 158; Confirmatory bias effect, 4, 29; Comers/Wells Adolescent Self-Report of Symptoms (CASS), 702r; Consciousness—on the Mental status examination (MSE), 42r; Contingency management (CM) ADHD (Attention-Deficit/ Hyperactivity Disorder), 300–301; substance use disorder, 793–796; Control delusions, 318r; Coolidge Axis II Inventory- Revised (CATI+), 920r; Coordinated Anxiety Learning and Management (CALM) study, 610, 611; Coping skills assessing stressors and, 29; Schizophrenia and other psychotic disorders and, 368–369; Counseling the Culturally Diverse: Theory and Practice (Sue and Sue), 87; Countertransference, 110; Couples therapy for substance use disorders, 796–798; Course and Outcome of Bipolar Youth (COBY) study, 493; CRAFFT, 778r; Cravings classical (Pavlovian) conditioning to understand, 766; as phasic response, 769; as physiologic symptom, 732; Crime adults with Autism Spectrum Disorder (ASD) and, 208...
Crime (continued)

Blueprint for Action to Prevent Youth Violence reducing rates of, 718

as condition that may be a focus of clinical attention, 95t

of high-risk behaviors related to ADHD, 274

See also Violent behavior

Crisis Intervention Handbook: Assessment, Treatment, and Research (Roberts), 117

Crisis interventions

clients in crisis, 114–117

clinician responsibilities, 118t
danger to self and others, 117, 118t, 120t

four-step crisis intervention model, 116t

overview of, 1060t

suicide myths, 119–121

Crisis Intervention Strategies (James and Gilliland), 116

Cross-Cutting Symptom Measures (DSM-5), 63, 73, 79

Cultural competence

ADDRESSING (acronym for within-group) diversity factors, 15t

intake interview and clinician, 14–16

multicultural sensitivity and multicultural humility

importance to, 15

three components of, 15

See also Diversity

Cultural differences

Autism Spectrum Disorder (ASD), 179

Bipolar Disorders, 509–510

as diagnosis determination factor, 80t, 84–89

DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) considerations of, 68–69

Eating Disorders treatment considerations, 668, 670

Schizophrenia and other psychotic disorders and consideration of, 363

steps to include in the clinical intake and treatment, 15t

substance use disorders, 757–759

WHO studies on Schizophrenia outcomes and, 327

See also Diversity

Cultural formulation

Cultural Formulation Interview (CFI), 69, 86–87

Culture-Related Diagnostic Issues, 68, 73

as diagnosis determination factor, 80t, 84–89

DSM-5 section on, 73, 74

“Glossary of Cultural Concepts of Distress” (DSM-5), 74

intake interview questions on, 24t, 33–34

Cure Autism Now (CAN), 177

The Curious Incident of the Dog in the Night-Time (Haddon), 177

Current Behavior Scale (CBS), 277

Cyclothymic Disorder

central clinical and discriminating features, 519t

clinical presentation, 492–493

epidemiology, 475

onset, course, and life span considerations, 493–495

See also Bipolar Disorders I and II

Danger to self and others

assessment of, 118t–119

assessment of prior violent behavior, 123t

Autism Spectrum Disorder (ASD), 206–208

clinician responsibilities, 118t

common clinician errors in intervention of, 120t

interventions for suicidal or dangerous clients, 131t

Major NCD-AD and, 835–836

overview of, 117

risk factors for, 121–129

safety plan implementation in case of, 129, 131–132

Schizophrenia and other psychotic disorders, 354–356

substance abuse disorders and, 734–736, 781–782

ten-step documentation for suicidal or dangerous clients, 131t

See also Safety issues; Suicide risk; Violent behavior

DAP (Data Assessment Plan) format, 157

Dating relationships (intake interview), 35–36

Delirium

clinical presentation, 811–813

description of, 810–811

epidemiology, 808

etiology, 824–826

interview and assessment strategies, 838–842

onset, course, and life span considerations, 814–815

postdelirium care, 852–853

risk factors for, 830, 832t

terminalogy on, 807

treatment, 850–853

See also Neurocognitive disorders

Delirium tremens, 744, 824

Delusional Disorder

clinical presentation, 341–342

epidemiology of, 316

etiology of, 353

onset, course, and life span considerations, 343

presence of delusions with, 341

psychosocial functioning and, 342

specifiers of, 343–344

Delusions

Delusional Disorder and presence of, 341

differentiating overvalued ideas and, 317

Major Neurocognitive Disorders (Major NCD), 820

Schizophrenia symptom of, 317t–319

types, definition, and examples of, 318t

Dependent (pathological dependency), 875

Dependent Personality Disorder

clinical presentation, 878t, 901

common comorbidities, 923t

description of, 900–901

interview considerations for, 919

onset, course, and life span considerations, 901–902

specific treatment interventions for, 935t, 950–951

Depressive disorders

anxiety, OCD, and trauma disorders comorbidity with, 600

Bipolar Disorders differential diagnosis and, 514t, 517

clinical presentations of, 403–405, 409–411

diagnostic considerations, 390–446

epidemiology of, 401–403

etiology, 422–430

historical overview of, 400–401

intake considerations, 430–432, 433t

interview and assessment strategies, 433–439

Major Depressive Disorder (MDD-C), 399, 401–409, 413–469

medical conditions that resemble, 81t

onset, course, and life span considerations, 405–409, 411–412

Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) differential diagnosis and, 705t

Persistent Depressive Disorder (Dysthymia), 399, 409–469

specifiers, 413–422t

treatment of, 446–469

Depressive disorder specifiers

additional specifiers that apply across the mood disorders, 413–419

listed, 422t

severity/remission, 413

unique specifiers: Major Depressive Disorder, 419–421

unique specifiers: Persistent Depressive Disorder, 421

Depressive disorder treatment

antidepressants, 447t–455

electroconvulsive therapy (ECT), 444, 455–456

general principles in, 446–447

psychotherapy, 458–469

repetitive transcranial magnetic stimulation (r-TMS), 456–458

Detoxification, 787–788
Developmental milestones, 48–49, as diagnosis determination factor, 80, 84–89
intake interview on social and family histories and, 24, 34–36
interviewing parents about child’s, 48
older adults and tasks of, 53–54
variations in relevant cognitive processes during childhood, 51
Developmental assessment (Autism Spectrum Disorder), 211–213

Diagnosis
clinical skills related to, 70–71
comorbid and multiple, 73, 100–102
determining a, 78–102
general medical condition (GMC) considered during, 32, 79, 81–82
increasing suicide risk, 124–125
Not Otherwise Specified (NOS) category discarded in DSM-5, 63, 70, 98–99
parsimony principle of, 90
precedence principle of, 90
principal, 102
as representing an interpretation of an individual’s experience, 59
as similar to solving a mystery, 3
strategies for diagnostic decision making, 91t
See also Differential Diagnosis; Intake and interviewing; Psychiatric classification

Diagnosis determination
issues to consider for, 78–79
medical conditions resembling psychiatric disorders, 81t
other conditions that may be a focus of clinical attention, 95t–96t
overview of the seven steps of, 79–102
strategies for diagnostic decision making, 91t

Diagnosis determination steps
step 1: consider general/other medical or physical etiology, 79, 80, 81–82
step 2: consider substance-related or substance/medication-induced disorder, 80, 82–84
step 3: consider cultural, developmental, and diversity factors, 80, 84–89
step 4: consider differentiation between diagnostic groupings, 80, 89–93
step 5: consider discrimination within diagnostic group, 80, 93
step 6: assess impairment, distress, and resilience, 80, 93–96
step 7: resolve diagnostic uncertainty and assign a diagnosis, 81t, 96–102

Diagnostic considerations
ADHD (Attention-Deficit/Hyperactivity Disorder), 284–289
anxiety, OCD, and trauma disorders, 603–609
Autism Spectrum Disorder (ASD), 220–226
Bipolar Disorders, 513–520
Cyclothymic Disorder, 513–520
Eating Disorders, 664–666
neurocognitive disorders, 843–849
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 704–708
Personality Disorders, 926–932
Schizophrenia and other psychotic disorders, 370–378
substance use disorders, 785–786

Diagnostic criteria
considering differentiation between diagnostic groupings, 80t, 89–93
definition of, 76
exclusionary, 76–78, 90
monothetic criteria sets, 76
polythetic criteria sets, 76
subtypes and specifiers, 77
See also Mental disorders
Diagnostic groupings, diagnosis determination and considering differentiation between, 80t, 89–93
Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV), 921t
Diagnostic Interview for Social and Communication Disorders (DISCO), 215t, 217
Diagnostic Interview Schedule for Children and DSM-IV (DISC-IV), 57t
Diagnostic Interview Schedule for DSM-IV (DIS-IV), 56t

Diagnostic uncertainty
alternative or other disorders to consider, 98t
causes and common, 98t
discrimination determination factor, 81t, 96–102
strategies to resolve, 98t

Dialectical Behavior Therapy (DBT)
Binge-Eating Disorder (BED), 676–677
Borderline Personality Disorder, 935t, 942–944
Diathesis-stress model of Schizophrenia, 350

Differential Diagnosis
ADHD (Attention-Deficit/Hyperactivity Disorder), 284–289
anxiety, OCD, and trauma disorders, 603–607
Autism Spectrum Disorder (ASD), 220–225
Bipolar Disorders, 513–518

depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)] and characteristics, 439–446
DSM-5 determination of, 73
Eating Disorders, 664–667t
Major Neurocognitive Disorders (Major NCD), 843–848
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 705t–708
Personality Disorders, 926–932
Schizophrenia and other psychotic disorders, 370–378
substance use disorders, 785–786
See also Diagnosis
Disability adjusted life years (DALYs), 733
Disability Assessment Schedule (WHODAS), 64, 73, 94, 152
Discharge summary, 168
Discrete-trial training (DTT), 233–234
Discrimination as factor, 80t, 93
The Disease Concept of Alcoholism (Jellinek), 722
Disgust sensitivity, 543–544
Disinhibition, 819
Disorganizing thinking/speech, 317t, 320–321

Disruptive and conduct disorders
ADHD comorbidity with, 281–282, 286t
ADHD Differential diagnosis with, 288
See also Conduct Disorder (CD); Oppositional Defiant Disorder (ODD); Violent behavior

Disruptive Mood Dysregulation Disorder
ADHD differential diagnosis and, 286
children and diagnosis of, 483
historical overview of, 401
ODD and CD differential diagnosis and, 705t, 706
Dissociative disorders, 844t, 847, 892
Distress as factor, 80t, 93–96
Disulfiram (Antabuse), 788
Divalproex (or valproate), 525

Diversity
ADDRESSING (acronym for within-group) diversity factors, 15t
as diagnosis determination factor, 80t, 84–89
DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) considerations of, 68–69
Eating Disorders treatment considerations, 668, 670
increasing U.S. population, 14
steps to include in the clinical intake and treatment, 15t
U.S. Census data to help educate about, 16
See also Cultural competence; Cultural differences
DO A Client MAP, 156
Documentation
case formulation report, 150
DAP format for, 157
discharge summary, 168
SOAP format for, 157
ten-step documentation for
suicidal or dangerous clients, 131

Domestic violence. See Partner
violence (domestic violence)

Dopamine hypothesis of
Schizophrenia, 351

Drug addiction, 728
See also Substance use disorders
Drug-facilitated rapes, 723

Drug treatment courts (DTCs), 787

Autism Spectrum Disorder (ASD)
adopted by the, 176–177
as communication tool, 65–66
compatibility with the ICD and
revisions, 70

Cross-Cutting Symptom Measures
of, 63, 73, 79
cultural interview available in the,
33
diagnostic criteria and clinical
judgment of the, 67–68
diversity considerations of the,
68–69
5-point Clinician-Rated
Dimensions of Psychosis
Symptom Severity scale in the,
337, 341
heterogeneity and comorbidity
classification model of, 66–67
major areas of stressors identified
by the, 39
multiaxial diagnostic system
abandoned in, 64
organization of the, 71–78
overview of the classification
system of the, 63–64
potential for stigma and self-
fulfilling prophecy issue of, 69
refamiliarize yourself to prepare
for intake interview, 4
reliability at the expense of validity
issue of, 68
strengths and limitations of the,
65–70
See also American Psychiatric
Association (APA); Psychiatric
classification; specific disorder

DSM-5 measures and model
(Section III)
Alternative DSM-5 Model for
Personality Disorders,
73, 74
Assessment Measures section, 73
Conditions for Future Study
section, 73, 74
Cultural Formulation section, 73,
74
DSM-5 organization
appendix of the, 74

diagnostic criteria, 76
of the diagnostic disorders
(Section II), 71–73
emerging measures and models
(Section III), 73–74
exclusionary criteria, 76–78, 90
key diagnostic terminology and
groupings, 74–75
syndromes, 75
DSM (Diagnostic and Statistical
Manual of Mental Disorders),
60–61, 314, 400, 473, 723
DSM-II (Diagnostic and Statistical
Manual of Mental Disorders,
Second Edition), 61, 252, 314,
400, 473, 680, 723
DSM-III (Diagnostic and Statistical
Manual of Mental Disorders,
Third Edition), 62, 176, 272,
313, 314, 325, 326, 400–401,
473, 540, 680, 723, 757, 806
DSM-III-R (Diagnostic and
Statistical Manual of Mental
Disorders, Third Edition
Revised), 62, 272, 473, 540,
577, 680, 724, 806
DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders,
Fourth Edition), 63, 176, 252,
272, 314, 326, 473, 540, 577,
807
DSM-IV-TR (Diagnostic and
Statistical Manual of Mental
Disorders, Fourth Edition, Text
Revision), 63, 70
Duration of untreated psychosis
(DUP), 327–328

Dysthymia. See Persistent
Depressive Disorder
(Dysthymia)

Early Screening of Autistic Traits
Questionnaire (ESAT), 214r,
215
Early Start Denver Model (ESDM),
235–236
Eating Disorder Diagnostic Scale
(EDDS), 662r
Eating Disorder Examination (EDE
16.0D), 662r
Eating Disorder Examination–Child
(EDE-Ch), 662r
Eating Disorder Examination–Questionnaire
(EDE–Q6.0), 662r
Eating Disorders
central clinical and discriminating
features, 667r
clinical presentation, 643–646,
648–650, 651–652
comorbidity, 661, 663–664
description of, 637–639
diagnostic considerations, 664–666
epidemiology, 641–643
etiology, 654–657
historical overview of, 639–641
intake considerations, 657–661
interview and assessment
strategies, 661, 662–663r
onset, course, and life span
considerations, 646–648,
650–651, 652–653
subtypes and specifiers, 653–654
treatment, 668–677
See also Anorexia Nervosa (AN);
Binge-Eating Disorder (BED);
Bulimia Nervosa (BN)

Eating disturbances (Autism
Spectrum Disorder), 198

Eating problems (intake interview),
79

Ecstasy (MDMA), 723, 727, 739,
748, 751–752

Educational and occupational factors
as condition that may be a focus of
clinical attention, 95
intake interview on history of, 24r,
36–37
Educational interventions
ADHD (Attention-Deficit/
Hyperactivity Disorder),
297–298, 304–306
Autism Spectrum Disorder (ASD)
and, 238–240
See also Schools

Elder and dependent adult abuse,
135, 835

Elderly population. See Older adults

Electroconvulsive therapy (ECT)
Bipolar Disorders, 527–528
for children and adolescents with
Schizophrenia, 331–332

Delusional Disorder treated with,
343
depressive disorders [MDD and
Persistent Depressive Disorder
(Dysthymia)], 444, 455–456

Emergency diagnostic centers/crisis
setting, 6t

Emotional processing theory
anxiety, OCD, and trauma related
disorders, 592–593
description of, 592

Emotional state
delirium and changes to, 813
Major Neurocognitive Disorders
(Major NCD) and changes in,
819–820
suicide risk and, 125–126

Employment. See Occupational and
educational factors

Enactive mind theory, 205

Enhanced perceptions, 189

Environmental factors
Autism Spectrum Disorder (ASD),
202–203
interventions for delirium,
851–852
Oppositional Defiant Disorder
(ODD) and Conduct Disorder
(CD), 698

Epidemiological Catchment Area
(ECA) study, 681

Epidemiology
ADHD (Attention-Deficit/
Hyperactivity Disorder),
253–254
Autism Spectrum Disorder (ASD),
177–179
Bipolar Disorders, 474–475
Eating Disorders, 641–643
Generalized Anxiety Disorder (GAD), 541
Hoarding Disorder, 541–542
Major Depressive Disorder (MDD), 401–402
neurocognitive disorders, 808–810
Obsessive-Compulsive Disorder (OCD), 541–542
Oppositional Defiant Disorder (ODD), 680–681
Panic Disorder, 540–541
personality disorders, 876–878
PTSD (Posttraumatic Stress Disorder), 542
Social Anxiety Disorder (Social Phobia), 540
Specific Phobia, 539–540
substance-related disorders, 724–728
Epilepsy, 218
Erotopanic delusions, 318r
Essay on Drunkenness (Trotter), 721
Ethical issues. See Legal and ethical issues
Ethnicity. See Racial/ethnic differences
Etiology
ADHD (Attention-Deficit/Hyperactivity Disorder), 268–272
anxiety, OCD, and trauma related disorders, 586–593
Autism Spectrum Disorder (ASD), 199–206
Bipolar Disorders, 495–501
delirium, 824–826
depressive disorders, 422–430
Eating Disorders, 654–657
neurocognitive disorders, 824–834
Opposition Defiant Disorder (ODD) and Conduct Disorders (CD), 692–698
Personality Disorders, 904–910
Schizoaffective Disorder, 351–352
Schizophrenia, 348–351
substance use disorders, 763–771
Evidence-based interventions, 153
Exclusionary criteria (DSM-5), 76–78, 90
Executive dysfunction theory, 205
Executive functioning deficits, 818–819
Exercise programs
promoting better physical health through, 395
Schizophrenia and other psychotic disorders, 395–396
Exposure and response prevention (ERP), 627–628, 629
Exposure therapy
PTSD (Posttraumatic Stress Disorder), 632–633
Social Anxiety disorder, 623
Expressed Emotion (EE)
Bipolar Disorders, 533
Schizophrenia and other psychotic disorders, 328–329, 391
Eyebrow Child Behavior Inventory (ECBI), 702r
Eye contact/gaze of Autism Spectrum Disorder, 182–183
Eye movement desensitization and reprocessing (EMDR) therapy, 634–635
Families
ADHD and family functioning difficulties, 266–267
Autism Spectrum disorder (ASD) and, 208–210
Eating Disorders and risk factor of, 657
interviewing children and their, 46–52
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 695–696
See also Parents
Families and Schools Together (FAST) Track program, 715
Family caregivers
Project REACH on Alzheimer’s, 861–862
providing problem solving training to, 864
psychoeducation to Alzheimer’s, 863–864
respite care provided to, 865–866
strategies to increase health and well-being of, 866–867
support and opportunities to verbalize feelings, 862–863
support groups for, 866
Family environment models on substance use disorders, 770–771
Family-focused treatment (FFT)
Bipolar Disorders, 533–535
description of, 533
Family history
intake interview on development, and social and, 24r, 34–36
medical, 32
psychiatric and psychological, 29–30
See also Genetic factors
Family interventions
ADHD (Attention-Deficit/Hyperactivity Disorder), 297–298, 299–304
Anorexia Nervosa (AN), 672–673
behavioral family or couples therapy (BCT), 796–798
Bipolar Disorders, 522r
functional family therapy (FFT), 714–715
Major NCD-AD and other cognitive disorders, 860–867
multidimensional family therapy (MDFT), 714
substance use disorders, 796–799
Family Inventory of Life Events (FILE), 28
Family support
to Alzheimer’s caregivers, 862–863
Autism Spectrum Disorder (ASD) and, 240–243
Fear Survey Schedule (FSS), 598r
Federal Legal Appeals Project, 208
FIDO (Frequency, Intensity, Duration, and Onset), 28
90–91, 146
First 100 Days Tool Kit (Autism Speaks), 209
“First-rank” symptoms (FRDS) of Schizophrenia, 313, 317
5-point Clinician-Rated Dimensions of Psychosis Symptom Severity scale (DSM-5), 337, 341
Folstein Mini-Mental Status Exam (MMSE), 43, 456, 820
Food and Drug Administration (FDA)
black box warnings by, 454–455
medications approved for alcohol-free maintenance treatment by, 789
medications to treat opioid dependence approved by, 790, 791
memantine approved for NCD-AD by the, 855–856
prohibition of thimerosal in vaccines by, 203
Foothill Alliance for Autism (Los Angeles), 228
Friendships. See Peer relationships
Functional family therapy (FFT), 714–715
Functional impairment assessment description of, 152
Schizophrenia and other psychotic disorders and, 368
GABA (gamma-aminobutyric acid), 754, 763
GAIN tool (goal setting, action planning, initiating treatment, and nurturing motivation), 385
Gambling Disorder, 720
Gateway hypothesis, 755–756
Gender differences
ADHD (Attention-Deficit/Hyperactivity Disorder), 253, 255–256
alcohol-related causes of death and, 743
Autism Spectrum Disorder (ASD), 178
Conduct Disorder (CD), 681, 687
Eating Disorders, 641–642, 643
Schizophrenia outcome and, 329r
suicide rates and, 117
Gender-Related Diagnostic Issues (DSM-5), 68, 73
General Behavior Inventory (GBI), 506r
Generalized Anxiety Disorder (GAD)
central clinical and discriminating features, 607, 608r
clinical presentation, 560–563
Generalized Anxiety Disorder (GAD) (continued)
diagnostic considerations, 603–609
epidemiology, 541
etiology, 586–593
intake considerations, 593–596
interview and assessment strategies, 596–603
medical conditions that resemble, 817
medication for, 617–618
onset, course, and life span considerations, 563–565
overview of, 559–560
psychological treatments, 626–627
See also Anxiety disorders
Generalized Anxiety Disorder (GAD) (clinical presentation additional emotional, physical, and cognitive symptoms, 561
cognitive features, 561–562
tolerance of uncertainty, 562–563
uncontrollable worry, 560–561
General medical conditions (GMCs) anxiety, OCD, and trauma disorders and ruling out, 597, 599
anxiety, OCD, and trauma disorders differential diagnosis of, 604t
as condition that may be a focus of clinical attention, 96t
diagnostic consideration of, 32, 79, 81–82
diagnostic tips for, 83t
DSM-5 on, 72
Eating Disorders differential diagnosis of, 664–665
impact of substance use disorders on, 733–734t
some causes of delirium, 825t
General/medical hospitals common psychiatric disorders in setting of, 92t
finding out about past hospitalizations in, 3–4
See also Hospitalization Genetic factors ADHD (Attention-Deficit/Hyperactivity Disorder), 268–269
anxiety, OCD, and trauma related disorders, 588–589
Autism Spectrum Disorder (ASD), 199–200
Bipolar Disorders, 352, 495–496
Delusional Disorder, 353
Eating Disorders, 654–655
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 692–693
Personality Disorders, 905–907
Schizophrenia, 348–351, 353
Additional studies on substance use disorders, 764–765
See also Biological bases; Family history GHB (gamma hydroxyl-butate), 723
Gilliam Autism Rating Scale (GARS-3), 215t, 217
Girls’women. See Gender differences
Global Assessment of Functioning (GAF), 64
Global Developmental Delay and ASD, 226
“Glossary of Cultural Concepts of Distress” (DSM-5), 74
“Glossary of Technical Terms” (DSM-5), 74
Glossolalia, speech, 34
Grandiose delusions, 318t
Grandparents and ASD, 242–243
Gray Social Stories (C. Gray), 240
Grossly disorganized behavior, 317t,
321
Group therapy for Anorexia Nervosa, 672
A Guide to Crisis Intervention (Kanel), 116–117
Hallucinations auditory, 319
Schizophrenia symptom of, 317t, 319–320
tolerance to, 748
Hallucinogens demographics and statistics on use of, 726–727
intoxication symptoms, 741t, 747–752
ketamine, 748, 749
LSD (lysergic acid diethylamide), 722, 726, 748, 750
MDMA (ecstasy), 723, 727, 739, 748, 751–752
medical complications that can arise from, 734t
mescaline, 748, 750
Native American peyote use, 739, 750
neuropsychological impairment due to, 739
PCP (phencyclidine), 722, 727, 739, 741t, 747–748, 749
psilocybin, 748, 750
withdrawal from, 742t
See also Substance use disorders
Halo effect, 4
Handbook of Autism and Pervasive Developmental Disorders (Volkmar, Rogers, et al.), 211, 212
Handbook of Clinical Psychopharmacology for Therapists (Preston, O’Neal, and Talaga), 32
Health Insurance Portability and Accountability Act (HIPAA) forms required for intake interview, 4
on release of intake interview information, 13
reviewing Privacy Rule with client, 11
treatment plan confidentiality under the, 156, 158
Heroin Anonymous, 800
“Hippie movement,” 722
Hispanics
Project REACH on Alzheimer’s caregivers, 861–862
substance use disorders, 758–759, 761
See also Racial/ethnic differences
A History of Autism: Conversations With the Pioneers (Feinstein), 177
Histrionic (Hysterical PD), 873–874
Histrionic Personality Disorder clinical presentation, 878t,
894–895
common comorbidities, 923t
description of, 894
interview considerations for, 917
onset, course, and life span considerations, 896
specific treatment interventions for, 935t, 948–949
Hoarding Disorder clinical presentation, 571–574
epidemiology, 541–542
medication for, 614–615
onset, course, and life span considerations, 575–576
psychological treatments, 631–632
Schizophrenia and other psychotic disorders diagnostic differential and, 371t, 373
specifiers, 574–575
Home-based interventions for ASD, 233–236
Hopelessness model of depression, 426–427
Hospitalization antipsychotic medication nonadherence and related costs of, 384t
finding out about past, 3–4
when to consider, 140–141t
See also General/medical hospitals
Huffing inhalants, 752
Hyperactivity ADHD (Attention-Deficit/Hyperactivity Disorder) and, 257, 275–276
predominantly hyperactive/impulsive (ADHD-H/I), 260
presenting as restlessness, 257
Hyperresponsiveness, 189
Hypnotics demographics and statistics on the use of, 728
intoxication symptoms, 741t, 753–754
medical complications that can arise from, 734t
withdrawal symptoms, 742t, 754
See also Substance use disorders
Hyporesponsiveness, 188
ICD–6 (International Classification of Diseases, Sixth Edition) [WHO], 60, 61
| ICD–8 (International Classification of Diseases, Eighth Edition) [WHO], 61 |
|-----------------------------|-----------------------------|
| ICD–9 (International Classification of Diseases, Ninth Edition) [WHO], 74 |
| ICD–10 (International Classification of Diseases, Tenth Edition) [WHO], 74, 316, 339, 340, 680 |
| Identifying information, 24r, 26 |
| Impairment assessing functional, 152 |
| Conduct Disorder (CD), 684 as diagnosis determination factor, 80r, 93–96 |
| memory, 817 |
| Schizophrenia and other psychotic disorders treatment and issues of, 396–397 |
| WHODAS (Disability Assessment Schedule) on, 64, 73, 94, 152 |
| ADHD (Attention-Deficit/ Hyperactivity Disorder) and, 257 |
| Borderline Personality Disorder, 891–892 |
| intake interview on, 29 |
| Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 699–701, 706–708 predominantly hyperactive/impulsive (ADHD-H/I), 260 |
| Inattention ADHD and, 256, 275–276 ASD and joint attention deficits, 183–184, 205 delirium, 811 Major Depressive Disorder (MDD-C) and, 404–405 Mental status examination (MSE) on, 42t |
| The Incredible Years Program, 300, 304, 305 |
| Independent living and ASD, 246–248 |
| Individualized Education Plans (IEPs), 304 |
| Individual Placement and Support (IPS) model, 393, 394 Individuals with Disabilities Education Act (IDEA), 239 |
| Infantile Autism (Rimland), 175 |
| Informed consent children and, 10–11 Eating Disorders and, 658–659 elements to include in an, 10r ethical codes and principles of, 9–10 gathering the consent to treatment form for, 4 Major NCD-AD, 836–837 Schizophrenia and other psychotic disorders, 356–357 See also Treatment Inhalants demographics and statistics on use of, 727 intoxication and withdrawal from, 752 medical complications that can arise from, 734t |
| Intake interview process answering client questions, 22–23 avoiding confirmatory bias effect and halo effect during, 4, 29 cultural competence and, 14–16 effective questioning, 21–22 establishing rapport, 16–18 introducing the interview, 18–19 issues that impact interview effectiveness, 13–14 listening and attending, 19–20 reflections and interpretations, 20–21 setting the tone, 18 what to ask, 24r–44 |
| Intake interview questions chief complaint and presenting problem(s), 24r, 26 educational and occupational history, 24r, 36–37 family, development, and social history, 24r, 34–36 history of presenting problem(s), 24r, 26–29 identifying information, 24r, 26 legal history, 24r, 37 medical history, 24r, 31–32 psychiatric and psychological history, 24r, 29–30 resilience, strengths, competence, and challenges, 24r, 37–39 substance use history, 24r, 30 traumatic experiences, 24r, 31 |
| Intake interview safety issues ASAP’s violence triad data on, 7 attending to, 6–9 basic safety strategies, 8r what to look for in a review of client records, 7r |
| Intake interview questions about safety issues, 6–9 consider how the setting will guide the interview, 5–6r determine what you know and don’t know about your client, 3–4 gathering relevant paperwork, 4–5 |

Subject Index 1219

Intellectual disabilities ADHD comorbidity with learning disorders, 282 ADHD differential diagnosis with learning disorders, 285, 287 Autism Spectrum Disorder (ASD) and, 218–219, 221, 223 Major Neurocognitive Disorders (Major NCD) differential diagnosis, 843 Mental status examination (MSE) on intelligence and, 42r–43r psychological assessment of, 223–224 Interagency Autism Coordinating Committee (IACC), 177

| ICDS (International Classification of Diseases, Tenth Edition) (Tenth Edition) [WHO], 73, 314 |
| Initial interview safety issues attending to, 6–9 ASD and joint attention deficits, 206–210 immediate concerns that may come up during, 44, 45t |
| Initial interview process legal/ethical issues, 9–13 attention span considerations of, 46–55 preparing for the first interview, 3–9 strategies and tips for successful, 57–58 what to ask, 24r–44 See also Communication; Diagnosis; Interview and assessment strategies; Structured interviews |
| Initial interview questions determining what you know and don’t know about your client, 3–4 |
| Initial interview safety questions about safety issues, 6–9 consider how the setting will guide the interview, 5–6r determine what you know and don’t know about your client, 3–4 gathering relevant paperwork, 4–5 |
| Interview and interviewing ending the interview, 44–46 interviewing the client, 13–23 legal and ethical issues, 9–13 life span considerations of, 46–55 what to ask, 24r–44 |
| Interview and interviewing content of, 25–39 |
Intermittent Explosive Disorder, 708

International Classification of Diseases, Eighth Edition (ICD-8) [WHO], 61

International Classification of Diseases, Eleventh Edition (ICD-11) [WHO], 73, 314

International Classification of Diseases, Ninth Edition (ICD-9) [WHO], 74

Interview for Antisocial Behavior

Interview and assessment strategies

Interpersonal theories of depression, 465–466

Interpersonal psychotherapy (IPT)

Interoceptive avoidance, 556–557

International personality Disorder

International Consortium of Psychiatric Epidemiology (ICPE), 405

International personality Disorder Examination (IPDE), 56, 921

Intercourse avoidance, 556–557

Interpersonal and social rhythm therapy (ISRT), 531–533

Interpersonal psychotherapy (IPT)

Binge-Eating Disorder (BED), 676

Bulimia Nervosa (BN), 675

depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 465–466

description of, 465

Interpersonal theories of depression, 428

Interpretations

diagnosis as representing an individual’s experience and an, 59

intake interview reflections and, 20–21

Interview and assessment strategies

ADHD (Attention-Deficit/Hyperactivity Disorder), 274–276

anxiety, OCD, and trauma related disorders, 596–603

Autism Spectrum Disorder (ASD), 210–220

 Bipolar Disorders, 503–513

Cyclophthymic Disorder, 503–513

depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 433–439

Eating Disorders, 661, 662–663

neurocognitive disorders, 838–842

Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 701–703

Personality Disorders, 911–919

Personality Disorders Cluster A, B, C considerations, 914–919

Schizophrenia and other psychotic disorders, 357–370

substance use disorders, 773–782

See also Assessment; Client history; Intake and interviewing

Interview for Antisocial Behavior (IAB), 702

Interview settings

consider how it will guide the interview, 5

emergency diagnostic centers/crisis, 6

medical centers (VA, university, or rehabilitation), 6

outpatient (clinics/private practice), 6

preparing the, 5

Intimate partner violence. See Partner violence (domestic violence)

Intoxication. See Substance intoxication

Inventory of Callous-Unemotional Traits (ICU), 702

Inventory of Potential Communicative Acts (IPCA) questionnaire, 207

In vivo exposure, 620

Jealous delusions, 318

Joint attention deficits, 183–184, 205

Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 148

Kennedy Krieger Institute, 243

Ketamine, 748, 749

Kiddie Schedule for Affective Disorders and Schizophrenia (K–SAIDS), 55, 57

Kids’ Eating Disorders Survey (KEDS), 662

Korsakoff’s Syndrome, 736

K-SADS Mania Rating Scale, 507

LAAM (levo-alpha-acetylmethadol), 789–792

Lamotrigine, 525–526

Language

Autism Spectrum Disorder (ASD) with and without impairment, 191–192

glossolalia speech, 34

language disturbances, 811–812

Mental status examination (MSE) on, 42

to set the tone of intake interview, 18

when speaking to older adults, 52

See also Communication; Nonverbal communication

Latinos/Latinas

Project REACH on Alzheimer’s caregivers, 861–862

substance use disorders, 758–759, 761

See also Racial/ethnic differences

LEAP (Listen-Empathize-Agree-Partner) communication strategy, 385

Learning disorders

ADHD (Attention-Deficit/Hyperactivity Disorder) differential Diagnosis with, 285, 287

ADHD comorbidity with, 282

Oppositional Defiant Disorder (ODD) and Conduct Disorders (CD), 702–703

Learning Experiences: An Alternative Program for Preschoolers and Parents (LEAP), 237, 239

Learning theory paradigms

anxiety, OCD, and trauma related disorders, 590–591

description of, 590

Legal and ethical issues

adults with Autism Spectrum Disorder (ASD) and related, 196, 208

confidentiality, 11–13

drug treatment courts (DTCs), 787

informed consent, 4, 9–11, 836–837

mandated reporting, 138, 139, 599–600

Personality Disorders, 911

release of client information, 13

Legal history (intake interview), 24r, 37

Legislation

Americans with Disabilities Act (1990), 298, 304

Combating Autism Reauthorization Act or Public Law 112–32, 177

Health Insurance Portability and Accountability Act (HIPAA), 4, 11, 13, 156, 158

Individuals with Disabilities Education Act (IDEA), 239

National Prohibition Act (or Volstead Act) [1920], 722

U.S. PATRIOT Improvement and Reauthorization Act, 746

Levo-alpha-acetylmethadol (LAAM), 791–792

Lewinsohn’s behavioral model of depression, 427

LGBTQ individuals

intimate partner violence and, 133

suicide risk and, 128

Life charting (Bipolar Disorders), 507–508

Life span considerations

ADHD (Attention-Deficit/Hyperactivity Disorder), 261–263

Anorexia Nervosa (AN), 647–648

Autism Spectrum Disorder (ASD), 196–197

Bipolar Disorders, 479–484

Brief Psychotic Disorder, 339–341

Bulimia Nervosa (BN), 651

Conduct Disorder (CD), 688–692

Cyclothymic Disorder, 494–495

delirium, 815

Delusional Disorder, 343

as diagnosis determination factor, 87–89

Generalized Anxiety Disorder (GAD), 564–565
Neurocognitive disorders

LookMeintheEye: My Life With Major Depressive Disorderspecifiers

Major Depressive Disorder (MDD), 407–409
Major NCD-AD, 823–824
Obsessive-Compulsive Disorder (OCD), 570–571
Oppositional Defiant Disorder (ODD), 681–682, 688–691
Panic Disorder, 558–559
Persistent Depressive Disorder (Dysthymia), 412
PTSD (Posttraumatic Stress Disorder), 585–586
Schizoaffective Disorder, 336–337
Schizophreniform Disorder, 338
Social Anxiety Disorder (Social Phobia), 552–553
Specific Phobia, 545–547
substance use disorders, 754–757, 759–763
therapeutic relationship and treatment, 113–114
Lifestyle interventions promoting better physical health through, 395
Schizophrenia and other psychotic disorders, 395–396
Listening during intake interview, 19–20
Lithium
Bipolar Disorders, 523–525
description and mechanism of, 523
LSD (lysergic acid diethylamide), 722, 726, 748, 750
Maintenance treatment alcohol use disorder, 788–790
opioid use disorder, 790–792
Major Depressive Disorder (MDD) central clinical and discriminating features, 445r–446
chronic Major Depressive Disorder (MDD-C), 402, 410–411, 412
clinical presentation, 403–405
epidemiology of, 401–402
etiology; biological factors, 422–425
etiology; psychological theories, 425–430
intake considerations, 430–432, 433r
interview and assessment strategies, 433–439
introduction to, 399
onset, course, and life span considerations, 405–409
specifiers of, 413–422r
treatment of, 446–469
Major Depressive Disorder specifiers additional specifiers that apply across the mood disorders, 413–419
anxious distress, 415
atypical features, 414–415
with catatonia, 420–421
Melancholic Features, 413–414
mixed featured, 415–416
periparum onset, 417–419
psychotic features, 416–417
seasonal affect disorder (SAD), 419–420
severity/remission, 413
Major depressive episode (MDE)
Bipolar Disorders, 476–477
description of, 403–404
Major NCD-AD clinical presentation, 817–821
diagnostic considerations, 843–849r
intake considerations, 834–842
interview and assessment strategies, 838–842
NINCDS-ADRDA criteria revised, 821–823
onset, course, and life span considerations, 823–824
overview of, 807, 809–810, 827–829
risk factors for, 830–834
treatment, 853–867
See also NINCDS-ADREDACriteria for Alzheimer’s Disease
Major Neurocognitive Disorders
(Major NCD)
clinical presentation, 817–821
diagnostic considerations, 843–849r
intake considerations, 834–842
interview and assessment strategies, 838–842
overview of, 815–816
risk factors for, 830–834
substantial impairment requirement of, 808
treatment, 853–867
See also Neurocognitive disorders
Major VNCD clinical presentation, 817–821
intake considerations, 834–842
onset, course, and life span considerations, 824
overview of, 809–810
risk factors for, 830–834
treatment, 853, 854
The Making of a Therapist
(Sommers-Flanagan), 109
Malingering, 99–100
Malingering and factitious disorder, 847–848
Mandated reporting arising from trauma interviews, 599–600
importance of being familiar with laws on, 138, 139r
MAOIs (monoamine oxidase inhibitors)
anxiety, OCD, and trauma disorders, 613, 616
Depressive Disorders, 415, 423, 448, 452
Marginalization, 85
MBCT (mindfulness-based cognitive therapy)
depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 468–469
description and approach of, 468
MDMA (ecstasy), 723, 727, 739, 748, 751–752
Measles-mumps-rubella (MMR) vaccination, 203
Medical centers (VA, university, or rehabilitation) setting, 6r
Medical conditions. See General medical conditions (GMCs)
Medical detoxification, 787–788
Medical history family, 24r, 29–30, 32, 34–36
intake interview on, 24r, 31–32
Medication ADHD (Attention-Deficit/ Hyperactivity Disorder), 289–293
Anorexia Nervosa (AN), 673
anxiety, OBD, trauma-related disorders, 612–618
Binge-Eating Disorder (BED), 677
Bipolar Disorders, 521–527
black box warning consideration of, 454–455
Borderline Personality Disorder NICE guidelines on, 947–948
Bulimia Nervosa (BN), 675
delirium, 850–851
depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 415, 444, 447–455
Major NCD-AD, 854–857
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 716–717
pharmacologic treatments of substance use disorders, 787–792
Schizophrenia and other psychotic disorders, 325, 369, 380–385
See also specific medication; Substance use
Medication Adherence Rating Scale (MARS), 360r, 385
Medication-induced disorder, 80r, 82–84
Medication nonadherence
ADHD (Attention-Deficit/ Hyperactivity Disorder), 293–295
as challenge to treatment outcome, 163–165
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study on, 365, 384, 395
as condition that may be a focus of clinical attention, 96e factors in, 164r
GAIN tool (goal setting, action planning, initiating treatment, and nurturing motivation) to improve, 385
Medication nonadherence
(continued)
LEAP (Listen-Empathize-Agree-Partner) communication strategy to improve, 385
Medication Adherence Rating Scale (MARS), 360r, 385
strategies for improving adherence, 164r
treatment resistant depression consideration for, 452–454
Melancholia, 400
Melancholic Features
Bipolar Disorder, 485–486
depressive disorders, 413–414
Mementine, 855–856
Memory
cognitive disorders and impairment, 817
Mental status examination (MSE)
on, 42r
Men/boys. See Gender differences
Mental disorders
comorbidity and multiple, 73, 100–102
DSM-5 on syndromes of, 75
DSM-5 terminology and concepts related to, 74–75
See also Diagnostic criteria
Mentalization-based treatment (MBT), 935r, 945–946
Mental status examination (MSE)
areas typically covered in a, 40r
cognitive areas typically covered in a, 42r–43r
jotting down notes when giving the, 4
older adults and, 53
overview of the, 39–44
treatment preparation and planning using the, 107
Mescaline, 748, 750
Metabolic Syndrome, 395
Methadone maintenance programs, 790–791
Methamphetamine, 746–747
Methylphenidate (MPH), 290, 292, 293, 296
Michigan Alcohol Screening Test (MAST), 777r
Mild NCD due to HIV Infection, terminology on, 807
Mild Neurocognitive Disorder (NCD)
diagnostic considerations, 843–849r
Mild NCD due to HIV Infection, 807
modes impairment requirement of, 807
terminology on, 807
Millon Clinical Multiaxial Inventory III, 920r
Mindfulness-based cognitive therapy (MBCT)
depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 468–469
description and approach of, 468
Minnesotta Multiphasic Personality Inventory–2 (MMPI–2), 374, 920r
Modified CHAT-R-Follow-Up (M-CHAT-R/F), 213, 214r
Modified Checklist for Autism in Toddlers (M-CHAT), 213, 215
Molecular Genetics of Schizophrenia study, 349
Monitoring the Future survey, 724, 725, 726–727
Monoamine oxidase inhibitors (MAOIs)
anxiety, OCD, and trauma disorders, 613, 616
Depressive Disorders, 415, 423, 448, 452
Monothetic criteria sets, 76
Mood Disorder Questionnaire (MDQ), 506r
Mood disorders
ADHD comorbidity with, 282–283
ADHD differential diagnosis with, 286r, 287
anxiety, OCD, and trauma disorders differential diagnosis of, 604r, 605–606
Autism Spectrum Disorder (ASD) and, 219, 223r, 225
Bipolar Disorders, 81r, 471–535
depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 399–470
Eating Disorders comorbidity, 661, 663
Eating Disorders differential diagnosis of, 665
intake interview on symptoms of, 29
Major Neurocognitive Disorders (Major NCD) differential diagnosis, 844r, 845–847
medical conditions that resemble, 81r
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) differential diagnosis and, 705r, 706
Oppositional Defiant Disorder (ODD) and Conduct Disorders (CD) comorbidity, 704
Personality Disorders comorbidity, 922–924
psychodynamic theories of, 429–430
Schizophrenia and other psychotic disorders and symptoms of, 364–365
substance use disorder comorbidity with, 783
Motivational interviewing for dealing with client resistance, 17
substance use disorders, 772, 779–781
Motor dysfunction
Autism Spectrum Disorder (ASD), 197–198
Major Neurocognitive Disorders (Major NCD), 821
Multicultural sensitivity, 15
Multidimensional family therapy (MDFT), 714
Multidimensional Treatment Foster Care (MTFC), 716
Multimodal treatment
ADHD (Attention-Deficit/Hyperactivity Disorder), 295–297
Oppositional Defiance Disorder (ODD) and Conduct Disorders (CD), 715–716
Multimodal Treatment Study of Children with ADHD (MTA), 296–297, 302
Multiple disorders
comorbid and, 73, 100–102
principal diagnosis of, 102
Multisystemic or multimodal treatment (MST)
ADHD (Attention-Deficit/Hyperactivity Disorder), 295–297
Oppositional Defiance Disorder (ODD) and Conduct Disorders (CD), 715–716
Multicultural humility, 15
Music therapy, 860
The Myth of Mental Illness (Szasz), 61
Naltrexone, 789–790
Narcissistic, 874
Narcissistic Personality Disorder clinical presentation, 878r, 897
common comorbidities, 923r
description of, 896
interview considerations for, 917–918
onset, course, and life span considerations, 897–898
specific treatment interventions for, 935r, 949
Narcotics Anonymous, 800
National Alliance for Autism Research, 177
National Association of Social Workers (NASW), 9, 12, 109
National Center on Elder Abuse (NCEA), 135
National Centers of Excellence in Youth Violence Prevention, 717
National Coalition of Anti-Violence Programs (NCAPV), 133
National Comorbidity Study Replication (NCS-R), 92, 254, 403, 474, 537, 594
National Comorbidity Survey, 727
National Depressive and Manic Depressive Association (NMDA), 479
National Epidemiological Survey on Alcohol and Related Conditions (NESARC), 402, 571, 594, 595, 724, 726, 727, 758, 783, 784
National Institute of Mental Health Collaborative Psychiatric Epidemiological Studies, 553
National Institute of Mental Health (NIMH) Epidemiologic Catchment Area (ECA) survey, 725
National Institute of Mental Health’s (NIMH) Systematic Enhancement Program for Bipolar Disorder (STEP-BD), 487, 488, 512, 527, 530
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 783
National Institute on Drug Abuse (NIDA), 719, 733, 748, 749, 752, 753, 754, 763, 787
National Institutes of Mental Health, 736, 763–764
Native Americans
National Survey of American Life, 733, 747
National Study of American Life, 740
National Society of Autistic Children
National Research Council (NRC), 244
National Prohibition Act (or Volstead Act) [1920], 722
National Research Council (NRC), 244
National Latino and Asian American Study (NLAS), 402
National Institutes of Health (NIH), 603–609
epidemiology, 541–542
treatment, 586–593
historical overview of, 538–539
Hoarding Disorder, 371t, 373
intake considerations, 593–596
introduction to, 537–538, 596–603
medical conditions that resemble, 81t
medication for, 614–615
Obsessive Compulsive Disorder (OCD), 371t, 373
onset, course, and life span considerations, 569–571
psychological treatments, 627–632
Schizophrenia and other psychotic disorders and, 371t, 373–374
specifiers, 568–569
Obsessive-Compulsive Personality Disorder (OCPD)
clinical presentation, 878t, 903
common comorbidities, 923t
description of, 902
interview considerations for, 919
onset, course, and life span considerations, 903–904
specific treatment interventions for, 935t, 951–952
Obsessive-Compulsive personality traits, 875–876
Occupational and educational factors
ADHD and difficulties with, 264–266
Autism Spectrum Disorder (ASD) and, 248–249
as condition that may be a focus of
clinical attention, 95t
intake interview on history of, 24t, 36–37
See also Schools
Olanzapine, 526
Older adults
ADHD (Attention-Deficit/Hyperactivity Disorder) and, 262–263, 266
Anorexia Nervosa (AN), 648
Autism Spectrum Disorder (ASD) and, 196
Binge-Eating Disorder (BED), 653
Bipolar Disorders, 483–484
Bulimia Nervosa (BN), 651
demographics of U.S., 52
developmental tasks of, 53–54
diagnosis determination, 603–609
developmental or life span recommendations on, 88t
elder and dependent adult abuse of, 135, 835
Generalized Anxiety Disorder (GAD), 564–565
Hoarding Disorder, 576
intake interviewing of, 52–55
language to use when speaking to, 52

See also Delirium; Major Neurocognitive Disorders (Major NCD)
Neurodevelopmental disorders
ADHD (Attention-Deficit/Hyperactivity Disorder), 219–220, 222t, 226, 251–309
Autism Spectrum Disorder (ASD), 173–250
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) differential diagnosis and, 705–706
Schizophrenia and other psychotic disorders and, 371t, 372–373
Neurological symptoms of delirium, 813
Neuropsychological impairment
alcohol, 736–737
benzodiazepines, 739
cannabis, 737–739
cocaine and amphetamines, 737
due to other substances, 739
opiates, 738–739
Neurotransmitters
ADHD (Attention-Deficit/Hyperactivity Disorder) and, 270
Autism Spectrum Disorder (ASD) and, 202
Bipolar Disorders, 496–497
depressive disorders and abnormalities in, 423
dopamine, 763–764
how alcohol impacts, 736
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 693–694
New York State Elder Abuse Prevalence Study, 135
New York State Psychiatric Institute, 244
New York Teacher Rating Scale For Disruptive and Antisocial Behavior, 702t
NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV or DISC), 277
NIMH’s Preschool ADHD Treatment Study (PATS), 292
NINCDS-ADREDA criteria for Alzheimer’s Disease, 821
See also Major NCD-AD Nonstimulant medication
atomoxetine (Strattera), 292
tricyclic antidepressants (TCAs), 292
Nonverbal communication
Autism Spectrum Disorder (ASD) and social, 182–184
during intake interview, 19–20
See also Language
Not Otherwise Specified (NOS) category, 63, 70, 98–99
Obsessive-Compulsive Disorder (OCD)
Body Dysmorphic Disorder (BDD), 371t, 373
central clinical and discriminating features, 607, 609t
clinical presentation, 565–568
diagnostic considerations, 603–609t
epidemiology, 541–542
etiology, 586–593
historical overview of, 538–539
Hoarding Disorder, 371t, 373
intake considerations, 593–596
introduction to, 537–538, 596–603
medical conditions that resemble, 81t
medication for, 614–615
Obsessive Compulsive Disorder (OCD), 371t, 373
onset, course, and life span considerations, 569–571
psychological treatments, 627–632
Schizophrenia and other psychotic disorders and, 371t, 373–374
specifiers, 568–569
Obsessive-Compulsive Personality Disorder (OCPD)
clinical presentation, 878t, 903
common comorbidities, 923t
description of, 902
interview considerations for, 919
onset, course, and life span considerations, 903–904
specific treatment interventions for, 935t, 951–952
Obsessive-Compulsive personality traits, 875–876
Occupational and educational factors
ADHD and difficulties with, 264–266
Autism Spectrum Disorder (ASD) and, 248–249
as condition that may be a focus of
clinical attention, 95t
intake interview on history of, 24t, 36–37
See also Schools
Olanzapine, 526
Older adults
ADHD (Attention-Deficit/Hyperactivity Disorder) and, 262–263, 266
Anorexia Nervosa (AN), 648
Autism Spectrum Disorder (ASD) and, 196
Binge-Eating Disorder (BED), 653
Bipolar Disorders, 483–484
Bulimia Nervosa (BN), 651
demographics of U.S., 52
developmental tasks of, 53–54
diagnosis determination, 603–609
developmental or life span recommendations on, 88t
elder and dependent adult abuse of, 135, 835
Generalized Anxiety Disorder (GAD), 564–565
Hoarding Disorder, 576
intake interviewing of, 52–55
language to use when speaking to, 52

Subject Index 1223
Older adults (continued)
Major Depressive Disorder (MDD) and, 407–408
Obsessive-Compulsive Disorder (OCD), 571
Oppositional Defiant Disorder (ODD), 683
Panic Disorder, 559
Persistent Depressive Disorder (Dysthymia), 412
PTSD (Posttraumatic Stress Disorder), 585–586
Schizophrenia in, 332–333
Social Anxiety Disorder (Social Phobia), 553
Specific Phobia, 546–547
substance use disorders, 761–763, 775
therapeutic interventions for, 154
See also Adults
On Being a Therapist (Kottler), 109
“On Being Sane in Insane Places” (Rosenhan), 61
One Flew Over the Cuckoo’s Nest
(Kesey), 61
Open-ended questions, 21
Operant conditioning, 766–767
Opioids
demographics and statistics on the use of, 727–728
intoxication symptoms, 741t,
752–753
medical complications that can arise from, 734
neuropsychological impairment due to, 738–739
treatments for dependence on, 790–792
withdrawal symptoms, 742r, 753
See also Substance use disorders
Oppositional Defiant Disorder (ODD)
central clinical and discriminating features, 707r
clinical presentation, 681–682
comorbid disorders, 703–704
diagnostic considerations, 704–708
environmental factors, 698
epidemiology, 680–681
etiology of, 692–698
historical overview, 678–680
intake considerations, 698–701
interview and assessment strategies, 701–703
introduction to, 677–678
medication, 716–717
onset, course, and life span considerations, 682–683, 688–690
poor peer relationships, 687–688
risk and protective factors for, 697t
specifiers, 685
treatment, 708–717
See also Disruptive and conduct disorders
Outline for Cultural Formulation (DSM-5), 69
Outpatient (clinics/private practice) setting, 6r
Overvalued ideas, 317
Paliperidone, 526
Panic Disorder
central clinical and discriminating features, 607, 608r
clinical presentation, 553–557
description of, 542–543
diagnostic considerations, 603–609
disguist sensitivity, 543–544
epidemiology, 540–541
etiology, 586–593
intake considerations, 593–596
interview and assessment strategies, 29, 596–603
medical conditions that resemble panic attacks and, 81r
medication for, 613–614, 617
onset, course, and life span considerations, 557–559
psychological treatments, 624–627
situation-specific fear, 543
See also Anxiety disorders
Panic Disorder clinical presentation anxious apprehension, 555–556
forms of avoidance (including agoraphobia), 556–557
panic attacks, 553–555
Panic Disorder Severity Scale (PDSS), 598r
Paperwork (intake interview), 4–5
Paranoid, 871
Paranoid Personality Disorder
clinical presentation, 878r,
882–883
common comorbidities, 923r
description of, 882
interview considerations for, 914–915
onset, course, and life span considerations, 883–884
specific treatment interventions for, 934r, 936–937
Parent-Child Interaction Therapy (PCIT), 300, 713–714
Parent-Child Relational Problems
ADHD differential diagnosis with, 286r, 288–289
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) differential diagnosis and, 705r
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) interviews on, 701
Parent Daily Report (PDR), 702r
Parent management training (PMT) programs, 299, 712–713
Parents
Autism Spectrum disorder (ASD) and, 208–210, 240–243
behavioral parent training (BPT) of, 299–304
informed consent of children and role of, 10–11
Parenting (STEPP) Program, 299–304
Parenting (STEPP) Program, 300, 713–714
Parent–child interaction therapy (PCIT), 161–162
Parsimony principle of diagnosis, 90
Partner violence (domestic violence) as condition that may be a focus of clinical attention, 95t
definitions of, 133r
interviews of victims of, 36
overview of, 132–133, 135
See also Abuse and neglect
PCP (phencyclidine) demographics and statistics on use of, 727
“hippie movement” encouraging use of, 722
intoxication symptoms, 741t,
747–748, 749
neuropsychological impairment due of, 739
Peer relationships
ADHD and bullying and deviant peers, 268
ADHD and difficulties with, 267–268
intake interview on friendships and, 35
OOD and CD both characterized by poor, 687–688
See also Social Anxiety Disorder (Social Phobia)
Penn State Worry Questionnaire (PSWQ), 599r
Persecutory delusions, 318r
Persistent Depressive Disorder (Dysthymia)
central clinical and discriminating features, 445r
clinical presentation, 409–411
epidemiology of, 402–403
etiology: biological factors, 422–425
etiology: psychological theories, 425–430
intake considerations, 430–432, 433r
interview and assessment strategies, 433–439
introduction to, 399
onset, course, and life span considerations, 411–412
specifiers of, 413–422r
treatment of, 446–469

Observe that the document contains various topics including but not limited to anxiety disorders, ADHD, substance use disorders, and cultural formulation. The subject index includes a range of diagnoses and treatment approaches, illustrating a comprehensive overview of mental health conditions and their management.
Persistent Depressive Disorder (Dysthymia) specifiers
additional specifiers that apply
across the mood disorders, 881

age of onset, 821
anxious distress, 415
atypical features, 414–415
course specifiers, 421
listed, 422r

Melancholic Features, 413–419
mixed featured, 415–416
peripartum onset, 417–419
psychotic features, 416–417

Personality Diagnostic Questionnaire
Personality Disorder Not Otherwise Specified (PDNOS), 953

Personality Disorders
anxiety, OCD, and trauma
disorders comorbidity with,
601–603
assessment measures, 919–922

Bipolar Disorders and, 512–513,
515r, 518
clinical presentation, 878–881
Comorbidity, 922–925
demographics and statistics on,
869–870
diagnostic considerations,
926–932
dimensional conceptualization of,
952–954

Eating Disorders comorbidity,
663–664
epidemiology, 876–878
etiology of, 904–910
historical overview, 870–876
intake considerations, 910–926
interviews and assessment
strategies, 911–919

Minnesota Multiphasic
Personality Inventory–2
(MMPI–2), 374

Other Specified PD or Other
Unspecified PD, 904

Schizophrenia and other psychotic
disorders and, 372r, 375
substance use disorder,
comorbidity with, 784–785
treatment, 932–954

Personality Disorders: Cluster A
description of, 881
diagnostic considerations,
926–931
etiology, 904–910
interview considerations for,
914–916

Paranoid Personality Disorder,
878r, 882–884, 914–915, 923r,
934r, 936–937

Schizoid Personality Disorder,
878r, 884–885, 915, 923r, 934r,
937–938

Schizotypal Personality Disorder,
878r, 885–887, 915–916, 923r,
934r, 938–939

Personality Disorders: Cluster B
Antisocial Personality Disorder
(ASPD), 708, 785, 878r,
888–890, 916, 923r, 935r,
939–940

Borderline Personality Disorder,
515r, 518, 785, 878r, 890–894,
916–917, 923r, 935r, 940–948
description of, 887
diagnostic considerations,
926–930, 931
etiology, 904–910

Histrionic Personality Disorder,
878r, 894–898, 917, 923r, 935r,
948–949

interview considerations for,
916–918

Narcissistic Personality Disorder,
878r, 896–898, 917–918, 923r,
935r, 940

Personality Disorders: Cluster C
Avoidant Personality Disorder,
878r, 898–900, 918–919, 923r,
935r, 949–950

Dependent Personality Disorder,
878r, 900–902, 919, 923r, 935r,
950–951
description of, 898
diagnostic considerations,
926–930, 932
etiology, 904–910

interview considerations for,
918–919

Obsessive–Compulsive Personality
Disorder (OCPD), 878r,
902–904, 919, 923r, 935r,
951–952

Personality Disorder Scales
(MMPI-PD), 920r

Peyote, 739, 750

Physicians’ Desk Reference (PDR),
32, 293

Physiologic symptoms

cravings, 732
tolerance, 730–732
withdrawal, 730, 732

Picture Exchange Communication
System (PECS), 231

Pittsburgh Youth Study, 680

Pivotal response training (PRT),
234–235, 244–245

Play
Autism Spectrum Disorder (ASD)
and impairments in, 185–186

pivotal response training (PRT) to
support recess, 234–235,
244–245
sensory, 185
See also Children
Polythetic criteria sets, 76

Positive and Negative Syndrome
Scale (PANSS), 328, 360r

Positive Parenting Program (Triple
P), 712–713

Postdelirium care, 852–853

POTS II study, 630

Practicewise (Chorpita), 153

Precedence principle of diagnosis, 90

Premature treatment termination,
161–163

Preschool developmental variations,
51r

Presenting problem(s)

chief complaint and, 24r, 26
CLIENTS mnemonic on aspects
of, 26–27r, 48, 146

FIDO (Frequency, Intensity,
Duration, and Onset) of, 28,
90–91, 146

history of, 24r, 26–29

Presidential Task Force on
Evidence-Based Practice
(APA), 153

Preventing Youth Violence:
Opportunities for Action,
717–718

PRIDE survey (2009–2010), 760

Principal diagnosis, 102

Privacy Rule (HIPAA), 11

Problem lists

domains or target areas, 144r

identification of, 143, 145
priortizing problems, 145–146

Problem-Solving Skills Training
(PSST), 712

Program for the Education and
Enrichment of Relational Skills
(PEERS), 244

Progressive muscle relaxation
(PMR), 627

Project MATCH study on,
801–802

Project REACH: Resources for
Enhancing Alzheimer’s
Caregiver Health, 861, 864

Promoting Alternative Thinking
Strategies (PATHS), 300

Prototypes (DSM-5), 75

Provisional specifiers, 99

Psilocybin, 748, 750

Psychiatric and psychological history
intake interview on, 24r, 29–30

major domains of psychiatric
symptomatology, 29

Psychiatric classification

DSM-III to DSM-IV-TR, 62–63
evolution of the DSM system of,
60–61

the history of, 59–60

modern systems for, 61–62

WHO’s ICD-6 inclusion of, 60

See also Diagnosis; DSM-5

(Diagnostic and Statistical
Manual of Mental Disorders,
Fifth Edition)

Psychiatric emergency team (PET),
141

Psychiatric inpatient setting, 92r

Psychosocial assessment

using diathesis–stress models,
769–770

as ADHD treatment, 297–298
to Alzheimer’s caregivers,
863–864

Panic Disorder, 624–625

Psychodynamic theories

Bipolar Disorders, 501

Eating Disorders, 656

mood disorders, 429–430

substance use disorders,
769–770

Psychoeducation

as ADHD treatment, 297–298
to Alzheimer’s caregivers,
863–864

Panic Disorder, 624–625

Psychodynamic theories

Bipolar Disorders, 501

Eating Disorders, 656

mood disorders, 429–430

substance use disorders,
769–770

Psychoeducation

as ADHD treatment, 297–298
to Alzheimer’s caregivers,
863–864

Panic Disorder, 624–625
Psychoeducation (continued)
Schizophrenia and other psychotic disorders, 386–387

Psychological assessment
intellectual disabilities, 223–224
treatment intervention plan and role of, 146–147

Psychological theories

ADHD (Attention-Deficit/ Hyperactivity Disorder), 271–272
Autism Spectrum Disorder (ASD), 203–206
Bipolar Disorders, 499–501
depressive disorders, 425–430
Eating Disorders, 656–657
enactive mind theory, 205
executive dysfunction theory, 205
joint attention deficits, 205
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 694–698
Personality Disorders, 907–910
substance use disorders, 766–771
weak central coherence (WCC) theory, 205

Psychomotor disturbances of delirium, 813

Psychopathy Checklist Revised (PCL-R), 129

Psychosis

5-point Clinician-Rated
Dimensions of Psychosis
Symptom Severity scale (DSM-5) for, 337
medical conditions that resemble, 81

Schizoaffective Disorder and occurrence of, 334–335

Psychosocial functioning

(Delusional Disorder), 342

Psychosocial interventions

ADHD (Attention-Deficit/ Hyperactivity Disorder), 298–299
functional family therapy (FFT), 714–715
Major NCD-AD and VNCD, 857–858
Oppositional Defiant Disorder (OD) and Conduct Disorder (CD), 711–715
Parent-Child Interaction Therapy (PCIT), 713–714
Parent management training (PMT) programs, 299, 712–713
Positive Parenting Program (Triple P), 712–713
Problem-Solving Skills Training (PSST), 712

Psychotherapy

Anorexia Nervosa (AN), 671–673
anxiety, OCD, trauma disorders, 619–635
behavioral weight loss therapy, 677
Bipolar Disorders, 528–535
Bulimia Nervosa (BN), 674–675

Cognitive Behavioral Analysis
System of Psychotherapy (CBASP), 462–464
depressive disorders (MDD and Persistent Depressive Disorder (Dysthymia)), 458–462
Dialectical Behavior Therapy (DBT), 676–677
family-focused treatment (FFT), 533–535
interpersonal and social rhythm therapy (ISRT), 531–533
Interpersonal psychotherapy (IPT), 465–466, 675, 676
MBCT (mindfulness-based cognitive therapy), 468–469
Schizophrenia and other psychotic disorders, 387–389
substance use disorders, 792–799
See also Cognitive behavioral therapy (CBT)

Psychotic disorders

anxiety, OCD, and trauma
disorders differential diagnosis of, 603, 604r, 605
Brief Psychotic Disorder, 315–316, 339–341
cognitive difficulties and, 347–348
delirium, 812
Delusional Disorder, 316, 341–344, 353
depressive disorders (MDD and Persistent Depressive Disorder (Dysthymia)), 440r, 442
diagnostic considerations, 370–378
diminished insight into illness characteristic of, 344–345
historical overview of, 312–314
intake considerations, 353–357
interview and assessment strategies, 357–370
introduction to the topic of, 311–312
Major Neurocognitive Disorders (Major NCD) differential diagnosis, 843, 844r, 845
Schizoaffective Disorder, 315–316, 333–337, 351–352
Schizophreniform Disorder, 337–339, 352–353
Schizotypal Personality Disorder, 348
substance use disorder comorbidity with, 784
suicide risk, 345–347
treatment interventions, 378–397
See also Schizophrenia

Psychotic disorders differential diagnosis among the psychotic disorders, 375–378
Bipolar Disorders, 514r, 516–517
cognitive disorders, 370, 371r, 372
neurodevelopmental disorders, 371r, 372–373
obsessive compulsive and trauma and stressor-related disorders, 367–368, 371r, 373–374

personality disorders, 372r, 375
substance-induced disorders, 365–366, 372r, 374–375

Psychotic disorders intake considerations
informed consent, 356–357
listed, 355r
rapport, 353–354
risk of danger to self and others, 354–356

Psychotic disorders interview/ assessment measures for, 359–360
assess resources, coping, and other strengths, 368–369
collaboratively determine treatment goals, 369–370
determine cultural and developmental influences on symptom experience, 363
determine prodromal symptoms, 362–363
evaluate negative symptoms, 362
evaluate positive symptoms, 358, 360–362
inquire about level of functioning, 368
overview of, 357–358
review medication issues, 369
screen for comorbid symptoms and disorders, 364–368

Psychotic disorders treatment
cognitive behavioral therapy (CBT), 387–389
cognitive remediation, 394–395
exercise and lifestyle interventions, 395–396
family-based interventions, 390–392
financial issues and disability issues of, 396–397
general principles in, 378–380
medication for, 325, 369, 380–385
psychoeducation, 386–387
social skills training (SST), 389–390
vocational rehabilitation, 392–394

Psychotic experiences

intake interview on, 29
Major Neurocognitive Disorders (Major NCD) and symptoms of, 820

Psychotropic medications, 856–857

PTSD (Posttraumatic Stress Disorder)
ASD and parents who suffer from, 608
central clinical and discriminating features, 607, 609r
clinical presentations, 577–582
combat experiences that should prompt questions on, 37
diagnostic considerations, 603–609r
epidemiology, 542
etiology, 586–593
treatment intervention plan and role of, 146–147

Substance-induced disorders, 365–366, 372r, 374–375

schizophrenia and other psychotic disorders, 386–387

seen, 81

See also Schizophrenia
exploration of psilocybin and LSD in treatment of, 748
intake considerations, 593–596
intake interview on symptoms of, 29
interview and assessment strategies, 596–603
mandated reporting that may arise from interviews on, 599–600
medical conditions that resemble, 81
medication, 615–616, 618
onset, course, and life span considerations, 583–586
overview of, 576–577
psychological treatments, 632–635
Schizophrenia and other psychotic disorders and, 367–368, 371r, 374
specifiers, 582–583
See also Trauma and stressor related disorders
Questioning
by clients during intake interviews, 22–23
by clinicians during intake interviews, 24t–44
effective intake interview, 21–22
Questions
closed-ended, 21
intake interview, 24t–44
open-ended, 21
Quitapine, 526
Racial/ethnic differences
Autism Spectrum Disorder (ASD), 179
Eating Disorders and, 638–639, 641, 643
Eating Disorders treatment considerations, 668, 670
Major Depressive Disorder (MDD), 401–402
mental illness stigma of elders and, 52
Project REACH on Alzheimer’s caregivers, 861–862
substance use disorders, 757–759, 761
suicide rates and, 117
See also specific population
Rape drugs, 723
Rapport
anxiety, OCD, and trauma related disorders and establishment of, 993–994
Autism Spectrum Disorder (ASD) and establishment of, 206
Bipolar Disorders and establishment of, 501–502
description of, 17
intake interview and establishment of, 16–18
Major NCD-AD, 834–838
Personality Disorders, 910–911
Schizophrenia and other psychotic disorders intake and, 353–354
substance use disorders and establishment of, 772–773
See also Client resistance
Reduplicative paranoia, 820
Reference delusions, 318
Referral to other providers, 141–142
Reflections
different levels of reflective responses, 20
intake interview interpretations and, 20–21
Relapse prevention (RP), 792–793
Relationships
ADHD and difficulties with, 266–268
Autism Spectrum Disorder (ASD) and impairments in social, 181–182, 184–190
as condition that may be a focus of clinical attention, 95t
intake interview on, 35–36
ODD and CD both characterized by poor peer, 687–688
suicide risk and lack of support and, 127–129
See also Social environment;
Therapeutic relationship
Repetitive transcranial magnetic stimulation (r-TMS), 456–458
Research Domain Criteria—RDoC, 68
Resilience
as diagnosis determination factor, 80r, 93–96
intake interview on strengths, competence, challenges, and, 24t, 37–39
The Road to Resilience (APA) on, 38
Restrictive and repetitive behaviors (RRBs), 186–187, 189, 206
Risperidone, 526
The Road to Resilience (APA), 38, 116
Rohypnol (flunitrazepam), 723
Route of administration model of substance use, 756
SAD PERSONS Scale, 121
Safety issues
Autism Spectrum Disorder (ASD), 206–208
immediate concerns that may come up during intake interview, 44, 45r
initial interview, 6–9
Major NCD-AD, 837–838
safety plan implementation, 129, 131–132
See also Danger to self and others; Suicide risk
SAMHSA (Substance Abuse and Mental Health Services Administration), 719, 720, 724, 725, 726, 727, 755, 758
The Saving Inventory—Revised, 599t
Scale for Suicide Ideation, 128
Scale to Assess Unawareness of Mental Disorder (SUMD), 360t
Schedule for Affective Disorders and Schizophrenia (SADS), 56t
Schedule for Affective Disorders for School-Age Children Present and Lifetime Version (K-SADS-PL), 277
Schedule for Nonadaptive and Adaptive Personality (SNAP-2), 920t
Schedule for the Assessment of Negative Symptoms (SANS), 359r
Schedule for the Assessment of Positive Symptoms (SAPS), 359r
Schema-focused therapy (SFT), 935r, 946–947
Schizoaffective Disorder
as “the Alsace Lorraine of psychiatry,” 352
Brief Psychotic Disorder and, 315–316
clinical presentation of, 334–335
description and diagnosis of, 333–334
epidemiology of, 315
etiology of, 351–352
onset, course, and life span considerations of, 335–337
specifiers of, 337
Schizoid, 871–872
Schizoid Personality Disorder
clinical presentation, 878t, 884–885
common comorbidities, 923r
description, 884
interview considerations for, 915
onset, course, and life span considerations, 885
specific treatment interventions for, 934t, 937–938
Schizophrenia
Autism Spectrum Disorder (ASD) and, 225–226
childhood-onset, 329–332
clinical presentation of, 316–323
cognitive problems associated with, 347–348
cross-cultural outcomes of, 327
diagnostic considerations, 370–378
diathesis-stress model of, 350
dopamine hypothesis of, 351
duration of untreated psychosis (DUP) outcome in, 327–328
epidemiology of, 314–315
etiology of, 348–351
expressed emotion (EE) and, 328–329, 391
genetic factors of, 348–351, 353
historical overview of, 312–314
intake considerations, 353–357
interview and assessment strategies, 357–370
introduction to the topic of, 311–312
life span considerations of, 329–333
long-term outcome studies of, 325–327
Schizophrenia (continued)
negative symptoms of, 317r,
321–323
in older adults, 332–333
onset and course of, 323–325
positive symptoms of, 317r–321
predictors of outcome in, 329r
Schneiderian “first-rank”
symptoms (FRDS) of, 313, 317
specifiers of, 333
suicide risk among individuals
with, 346r
treatment interventions, 378–397
See also Psychotic disorders
Schizophrenia differential diagnosis
cognitive disorders, 370, 371r, 372
neurodevelopmental disorders,
371r, 372–373
obsessive compulsive and trauma
and stressor-related disorders,
362–368, 371r, 373–374
personality disorders, 372r, 375
substance-induced disorders,
365–366, 372r, 374–375
Schizophrenia intake considerations
informed consent, 356–357
listed, 355r
rapport, 353–354
risk of danger to self and others,
354–356
Schizophrenia interview/assessment
strategies
assessment measures for,
359r–360r
assess resources, coping, and other
strengths, 368–369
collaboratively determine
treatment goals, 369–370
determine cultural and
developmental influences on
symptom experience, 363
determine prodromal symptoms,
364–365
evaluate negative symptoms, 362
evaluate positive symptoms, 358,
360–362
inquire about level of functioning,
368
overview of, 357–358
review medication issues, 369
screen for comorbid symptoms
and disorders, 364–368
Schizophrenia Patient Outcomes
Research Team, 392
Schizophrenia Psychosocial
Outcomes Research Team
(PORT), 394, 396
Schizophrenia treatment
cognitive behavioral therapy
(CBT), 387–389
cognitive remediation, 394–395
effect and lifestyle
interventions, 395–396
family-based interventions,
390–392
financial issues and disability
issues of, 396–397
general principles in, 378–380
medication for, 325, 369,
380–385
psychoeducation, 386–387
social skills training (SST),
389–390
vocational rehabilitation,
392–394
Schizophreniform Disorder
clinical presentation of, 337–338
course specifiers of, 338–339
etiology of, 352–353
onset, course, and life span
considerations, 338
Schizotypal, 872
Schizotypal Personality Disorder,
348
clinical presentation, 878r,
886–887
common comorbidities, 923r
description of, 885–886
interview considerations for,
915–916
onset, course, and life span
considerations, 887
specific treatment interventions
for, 934r, 938–939
Schneiderian “first-rank” symptoms
(FRDS), 313, 317
SCHOOL program, 710–711
Schools
ADHD and difficulties at,
264–266
ADHD treatment interventions at,
304–306
considerations when clinician
works with, 305r
Families and Schools Together
(FAST) Track program, 715
Individualized Education Plan
(IEP) for students, 304
school-based ASD programs, 237
SCHOOL program for ODD and
CD, 710–711
school-wide positive behavioral
support (SWPBS) approach to
ASD adopted by, 239–240
See also Academic difficulties;
Educational interventions;
Occupational and educational
factors
Science (journal), 61
SCL-90-R (Symptom-Checklist
90–Revised), 280
Screening Tool for Autism in
Two-Year-Olds (STAT), 214r,
216–217
Seasonal affect disorder (SAD),
419–420
Sedatives
demographics and statistics on the
use of, 728
intoxication symptoms, 741r,
753–754
medical complications that can
arise from, 734r
withdrawal symptoms, 742r, 754
See also Substance use disorders
Selective serotonin reuptake
inhibitors (SSRIs), 448,
449–451
anxiety, OBD, trauma-related
disorders, 612, 613–614, 615
Borderline Personality Disorder,
947
Bulimia Nervosa (BN), 675
Depression Disorders, 448,
449–451, 454
Self-fulfilling prophecy issue, 69
Self-report measures
anxiety, OCD, and trauma related
disorders, 596–597
substance use disorders, 776,
777–778r
Seligman’s learned helplessness
model, 426
Sensory sensitivities/integration
deficits, 188–190
Sensory Sensitivity Questionnaire—
Revised, 220–221
Sequenced Treatment Alternatives to
Relieve Depression (STAR*D)
study, 448
Serotonin
Autism Spectrum Disorder (ASD),
202
experiences associated with, 202
Serotonin norepinephrine reuptake
inhibitors (SNRIs)
anxiety, OBD, trauma-related
disorders, 612, 613–614,
615–616
Depressive Disorders, 451
Serotonin transporter linked
promoter region (5-HTTLPR),
423
Settings
common psychiatric disorders in
different, 92r
interview, 5–6t
Sexual health
intake interview on difficulties or
conflicts, 29
Schizophrenia and other psychotic
disorders and, 395–396
Sexual orientation
do not assume a client’s, 36
LGBTQ individuals, 128, 133
Sexual violence
adult survivors of sexual abuse,
132, 138–140
child sexual abuse, 132, 138,
139
drug-facilitated rapes, 723
Signs (DSM-5 definition), 75
Silence and listening (intake
interview), 19
Situation-specific fear, 543
Skills: The Online Autism Solution
(CARD), 236
SLAP (Specificity, Lethality,
Availability, and Proximity), 129
Sleep disturbances
Autism Spectrum Disorder (ASD),
198
delirium sleep-wake cycle
changes, 812–813
intake interview on, 29
Sluggish cognitive tempo (SCT),
256
SNAPS (strengths, needs, abilities,
and preferences), 156
Anxiety disorders; Peer
Withdrawal

Social Anxiety Disorder (Social Phobia)
central clinical and discriminating features, 607–608
cognitive features, 548–549
diagnostic considerations, 603–609
epidemiology, 540
intake considerations, 593–596
interview and assessment strategies, 29, 596–603
onset, course, and life-span considerations, 545–547
specifiers, 544–545
systematic desensitization, 619–620
virtual reality (VR) therapy, 621
in vivo exposure, 620
See also Anxiety disorders
Specified Disruptive Behavior Disorder, 708
Specifiers
ADHD (Attention-Deficit/ Hyperactivity Disorder), 258–260
Autism Spectrum Disorder (ASD), 190–197
Bipolar Disorders, 484–492
Brief Psychotic Disorder, 341
Conduct Disorder (CD), 685–687
Delusional Disorder, 343–344
depressive disorders, 413–422
DSM-5 definition of, 77
Eating Disorders, 653–654
Hoarding Disorder, 574–575
Obsessive-Compulsive Disorder (OCD), 568–569
Oppositional Defiant Disorder (ODD), 683
provisional, 99
PTSD (Posttraumatic Stress Disorder), 582–583
Schizoaffective Disorder, 337
Schizophrenia, 333
Schizophreniform Disorder, 338–339
Social Anxiety Disorder (Social Phobia), 549–550
Specific Phobia, 544–545
substance-related disorders, 732–733
SSRIs (selective serotonin reuptake inhibitors)
anxiety, OBD, trauma-related disorders, 612, 613–614, 615–616
Depressive Disorders, 451
SOAP (Subjective Objective Assessment Plan) format, 157
Social Anxiety Disorder (Social Phobia)
central clinical and discriminating features, 607, 608
clinical presentation, 543–544
diagnostic considerations, 603–609
epidemiology of, 539–540
intake considerations, 593–596
interview and assessment strategies, 29, 596–603
onset, course, and life-span considerations, 545–547
specifiers, 544–545
systematic desensitization, 619–620
virtual reality (VR) therapy, 621
in vivo exposure, 620
See also Anxiety disorders
Stigma potential, 69
Substance intoxication and withdrawal from abuse of, 741t, 742t, 745–747
methylphenidate (MPH), 290, 293, 296
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD), 717
Stimulation-oriented approaches, 860
Strategic to Enhance Positive Parenting (STEP), 302, 713–714
Strengths
initial interview examination of positive qualities and, 38t
intake interview on resilience, competence, challenges, and, 24t, 37–39
Schizophrenia and other psychotic disorders and, 368–369
Stressors
assessing coping skills and, 29
cultural features of resilience and vulnerability and psychosocial, 86
DSM-5 identification of major areas of, 39
Striving To Reduce Youth Violence Everywhere (STRYVE)
Strategies Selector Tool, 718
Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD), 56t, 921t
Structured Clinical Interview for the DSM-5 (SCID-5), 55, 56t
Structured Interview for DSM-IV Personality-IV (SIDP-IV), 921t
Structured interviews
advantages and disadvantages of, 55, 57
anxiety, OCD, and trauma related disorders, 596–597
description of, 55
a sample of, 55, 56t–57t
Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD), 56t
Structured Clinical Interview for the DSM-5 (SCID-5), 55, 56t
See also Intake and interviewing
Subjective units of distress (SUDS), 158–159
Substance Abuse and Mental Health Services Administration (SAMHSA), 719, 720, 724, 725, 726, 727, 755, 758
Substance intoxication
alcohol, 740–744
cannabis, 741t
cocaine and amphetamines, 741t, 745–747
hallucinogens, 741t, 747–752
inhalants, 741t, 752
opioids, 741t, 752–753
overview of, 740
sedatives, hypnotics, and anxiolytics, 741t, 753–754
See also Withdrawal

Subject Index 1229
Substance-related disorders
  additional characteristics of, 733–739
  anxiety, OCD, and trauma
disorders comorbidity, 601
  Bipolar Disorders and, 512, 514r, 517
  clinical and diagnostic language
  used to discuss, 723–724
crystal methamphetamine, 598
clinical presentation, 728–732
comorbid disorders and, 782–785
cultural considerations, 757–759
depressive disorders comorbidity,
440r, 441–442
diagnostic considerations,
785–786
Eating Disorders comorbidity, 663
epidemiology, 724–728
etiology, 763–771
gateway hypothesis on, 755–756
historical overview of, 720–723
interview and assessment
strategies, 773–782
intoxication and withdrawal, 740,
741r, 742t
introduction to, 719–720
Major Neurocognitive Disorders
(Major NCD) differential diagnosis,
843, 844r
ODD and CD comorbidity, 704
ODD and CD differential
diagnosis and, 705t
onset, course, and life span
considerations, 754–757,
759–763
Personality Disorders
comorbidity, 923r, 924
specifiers, 732–733
treatment, 786–802, 803r
See also specific drug
Substance use
  ADHD (Attention-Deficit/ Hyperactivity Disorder) and
  risk of, 258, 284, 286r
  CAGE questions for taking a
  history of, 30
  club drugs, 722–723
  as diagnosis determination factor,
  80r, 82–84
  gateway hypothesis on, 755–756
  “hippie movement,” 722
  intake interview on history of, 24r,
  29, 30
  medical complications that can
  arise from, 734r
  physiologic symptoms of,
  730–732
  PTSD (Posttraumatic Stress
  Disorder), 581–582
  Schizophrenia and other psychotic
disorders, 365–366, 372r,
374–375
See also Alcohol use; Medication
Substance use disorder
  psychotherapeutic interventions
cognitive-behavioral therapy
(CBT), 792–793, 795
  contingency management (CM),
793–796
  relapse prevention (RP), 792–793
  Substance use disorders treatment
abstinence and harm reduction
approaches to, 786
  drug treatment courts (DTCs),
787
  pharmacologic, 787–792
  psychotherapeutic interventions,
792–799
  summary of interventions for, 803r
  12-step groups, 799–802
  Subtype diagnostic criteria (DSM-5),
77
  Sudden sniffing death, 752
  Suicide
  assessment of attempt and
  ideation, 123t–124
  CDC on rates of, 117
  Chronicological Assessment of
  Suicidal Events (CASE), 121
  interventions for dangerous clients
  or, 131t
  risk factors for, 121–129
  suicide myths, 119–121
  ten-step documentation for
  suicidal or dangerous clients,
131t
  Suicide assessment interviews
anxiety, OCD, and trauma related
disorders, 594–596
  Bipolar Disorders, 502–503, 504t
  how to give a, 128
  Suicide ideation, 123t–124
  Suicide risk
  ADHD and, 274
  antidepressant medications and
  increased, 454–455
  Bipolar Disorders, 504t
  diagnoses that can increase,
124–125
  individuals with schizophrenia
  and, 346r
  list of risk factors, 121–129
  MDD with Melancholic Features
  and, 414
  psychotic disorders and, 345–347
  SAD PERSONS Scale to assess,
121
  substance abuse disorders and,
734–736, 781
  violence and, 130t
See also Danger to self and others;
Safety issues
  Summer treatment programs (STPs),
301
  Supplemental Security Income (SSI),
397
  Supported employment (SE),
393–394
  Sutter-Eyburg Student Behavior
  Inventory-Revised (SEBI-R),
702t
  Symptom-Checklist-90–Revised
(SCL-90-R), 280
  Symptoms
  DSM-5 definition of, 75
  malingering individuals reporting,
99–100
See also specific symptom
  Suicide (DSM-5 definition), 75
  Synthetic marijuana (spice, K2, and
  fake weed), 723
  Systematic desensitization, 619–620
  Systematic Enhancement Program
for Bipolar Disorder (STEP-BD),
487, 488, 512, 527, 530
  TCAs (tricyclic antidepressants)
  anxiety, OBD, and trauma
disorders, 615, 616
  Depressive Disorders, 292, 415,
448, 449
  TEACCH for Toddlers, 237
  Teen Suicide Risk (King and
  colleagues), 129
  THC (delta-9-tetrahydrocannabinol),
744
  Theories on adults children of
  alcoholics (ACOA), 770–771
  Theory of mind (ToM), 204–205
  Therapeutic relationship
  client factors that may impact
treatment, 110–113
  clinician factors that may impact
treatment, 109, 112r
  countertransference, 110
  cultural features of, 86
  establishing and building the,
106r, 108–109
  life span considerations, 113r–114
See also Clients; Clinicians;
Relationships
  Therapist-initiated termination, 167
  Thinking in Pictures, expanded
dition: My Life With Autism
(Grandin), 177
  Thorazine (chlorpromazine), 380
  Thought disorder, 320
  Tics, 568–569
  Time line follow-back (TLFB)
  method, 775
  Tolerance
to hallucinogens, 748
  as physiologic symptom, 730–732
  Transference-Focused Psychotherapy
(TFP), 935r, 944–945
  Trauma and stressor related disorders
central clinical and discriminating
features, 607, 609r
diagnostic considerations,
603–609r
  etiology, 586–593
  historical overview of, 538–539
  intake considerations, 593–596
  interview and assessment
strategies, 596–603
  introduction to, 537–538
  mandated reporting that may arise
from interviews on, 599–600
  psychological treatments,
632–635
  Schizophrenia and other psychotic
disorders, 367–368, 371r,
373–374
  treatment, 610–635
See also Child abuse and neglect;
PTSD (Posttraumatic Stress
Disorder)
  Trauma-focused CBT (TF-CBT),
632
Traumatic experiences, intake interview on history of, 24r, 31

Treatment

Treat the Atypical Deficit Hyperactivity Disorder (Evans and Hoza), 276

Treatment

Treative Community Treatment (ACT) model of, 379–380, 393, 397

framework for, 105–168

nonadherence as condition that may be a focus of clinical attention, 96

obtaining client assent to, 11

substance use disorders, 786–802 tips and strategies for mastery of, 168–169 understanding by children and adolescents of, 46

See also Informed consent; Treatment interventions

Treatment and Education of Autistic and Related Communication Handicapped Children (TEACCH), 237

Treatment decision

commencement checklist, 142r disposition decisions for, 140–141 referral to other providers, 141–142

Treatment effectiveness/outcome assessment

challenges to, 161–165 factors in evaluating treatment progress, 159 multidimensional and symptom-specific measures, 159–160 overview of, 106r, 158 selecting an assessment measure for, 160–161 subjective units of distress (SUDS) for, 158–159

Treatment for Adolescents with Depression Study (TORDIA), 454

Treatment framework


Treatment interventions

ADHD (Attention-Deficit/ Hyperactivity Disorder), 289–309

Autism Spectrum Disorder (ASD), 226–249

Bipolar Disorders, 520–535 considerations for clinical disorders, 151r

Cyclothymic Disorder, 520–535 depressive disorders [MDD and Persistent Depressive Disorder (Dysthymia)], 446–469 documentation on, 157–158 evidence-based, 153 neurocognitive disorders, 850–867, 868r


See also Treatment

Treatment of Resistant Depression in Adolescents Study (TORDIA), 454

Treatment plans outline of a typical, 155r pitfalls to avoid, 155r Schizophrenia and other psychotic disorders and collaboratively determined goals, 369–370 SNAPs consideration of, 156 writing the, 154–157

Treatment resistant depression, 452–454


Triad of lethality, 124

Tricyclic antidepressants (TCAs) anxiety, OBD, and trauma disorders, 615, 616

Depressive Disorders, 292, 415, 448, 449

12-step groups

Alcoholics Anonymous (AA) as, 722, 794, 799–802

Cocaine Anonymous, 800

Heroin Anonymous, 800

Narcotics Anonymous, 800

Project MATCH study on, 801–802

Twelve-Step Facilitation (TSF), 800

The Twelve Steps and Twelve Traditions (AA), 799

Twin studies on substance use disorders, 764–765

Type 1 alcoholism, 766

Type 2 alcoholism, 766

Unspecified Disruptive, Impulse-Control, and Conduct Disorder, 708

U.S. Department of Education (DOE), 304

U.S. Department of Health and Human Services, 11, 52, 719

U.S. Department of Justice, 132

U.S. Drug Enforcement Administration, 749

The Use of Psychological Testing for Treatment Planning and Outcome Assessments (Maruish), 145, 161

U.S. National Survey of Children’s Health, 254

U.S. Office of Social Security, 397

U.S. PATRIOT Improvement and Reauthorization Act, 746

Vaccines Autism Spectrum Disorder (ASD) and controversy over, 203

FDA prohibition of thimerosal use in, 203

measles-mumps-rubella (MMR), 203

Valproate (or divalproex), 525

Veterans combat experiences that should prompt questions on PTSD, 37 intake interview on symptoms of PTSD in, 37 substance use disorders, 757

Vineland Adaptive Behavior Scales–II, 22

Violence triad (ASAP), 7

Violent behavior assessment of potential, 129 assessment of prior, 123 Conduct Disorder (CD), 683–684 interventions for suicidal or dangerous clients with, 131r safety plan implementation in case of, 129, 131–132 sexual, 132, 138–140, 723 suicidal risk and, 130r

See also Abuse and neglect; Crime; Danger to self and others; Disruptive and conduct disorders

Violent Rate Appraisal Guide (VRAG), 129

Virginia Twin Studies, 679

Virtual reality (VR) therapy, 621

Visual motor skills, 42

Virtual spatial difficulties, 820–821

The Vital Balance (Menninger), 61

VNCD. See Major VNCD

Vocational rehabilitation, 392–394

Washington University group, 62

The Wayward Youth (Aichorn), 679

Weak central coherence (WCC) theory, 205

Wender–Utah Rating Scale, 277
Wernicke’s Encephalopathy, 736–737
Western, Educated, Industrialized, Rich, and Democratic (WEIRD) countries, 179
Whites
Project REACH on Alzheimer’s caregivers, 861, 862
substance use disorders, 757, 761
See also Racial/ethnic differences
Wing’s triad (Autism Spectrum Disorder), 176, 177
Wisconsin Personality Disorders Inventory (WISPI-IV), 920t
Withdrawal
alcohol, 740–744
cocaine and amphetamines, 742t, 747
hallucinogens, 742t
inhalants, 752
opioids, 742t, 753
overview of intoxication and, 740
as physiologic symptom, 730, 732
sedatives, anxiolytics, and hypnotics, 742t, 754
See also Substance intoxication
Women/girls. See Gender differences
World Federation of Societies of Biological Psychiatry Guidelines, 381
World Health Organization Adult Self-Reports Scale (ASRS), 277
World Health Organization (WHO) cross-cultural outcomes of Schizophrenia studies by, 327
Disability Assessment Schedule (WHODAS) of the, 64, 73, 94, 152
DSM-5 compatibility with the ICD and revisions of the, 70
International Classification of Diseases, Eighth Edition (ICD-8) of the, 61
International Classification of Diseases, Eleventh Edition (ICD-11) of the, 73, 314
International Classification of Diseases, Ninth Edition (ICD-9) of the, 74
International Classification of Diseases, Seven Edition (ICD-7) of the, 61
International Classification of Diseases, Sixth Edition (ICD-6) of the, 60
International Classification of Diseases, Tenth Edition (ICD-10) of the, 74, 316, 339, 340, 680
ranking depression as the leading cause of mental health disability, 309
Yale–Brown Obsessive-Compulsive Scale (Y-BOCS), 598t
Years of lost life (YLL), 733
Young Mania Rating Scale (YMRS), 506t
Youth Risk Behavior Survey, 117
Ziprasidone, 526